US20200319196A1 - Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease - Google Patents
Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease Download PDFInfo
- Publication number
- US20200319196A1 US20200319196A1 US16/838,711 US202016838711A US2020319196A1 US 20200319196 A1 US20200319196 A1 US 20200319196A1 US 202016838711 A US202016838711 A US 202016838711A US 2020319196 A1 US2020319196 A1 US 2020319196A1
- Authority
- US
- United States
- Prior art keywords
- supar
- subject
- level
- cardiovascular disease
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 78
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 title claims abstract description 32
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 144
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 206010062237 Renal impairment Diseases 0.000 claims abstract description 29
- 230000005977 kidney dysfunction Effects 0.000 claims abstract description 29
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 79
- 206010019280 Heart failures Diseases 0.000 claims description 52
- 210000002216 heart Anatomy 0.000 claims description 50
- 238000002560 therapeutic procedure Methods 0.000 claims description 49
- 208000029078 coronary artery disease Diseases 0.000 claims description 43
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 33
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 29
- 208000020832 chronic kidney disease Diseases 0.000 claims description 26
- 229960002256 spironolactone Drugs 0.000 claims description 21
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 21
- 210000004351 coronary vessel Anatomy 0.000 claims description 19
- 210000003734 kidney Anatomy 0.000 claims description 19
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 18
- 208000033626 Renal failure acute Diseases 0.000 claims description 18
- 201000011040 acute kidney failure Diseases 0.000 claims description 18
- 230000003907 kidney function Effects 0.000 claims description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 16
- 238000002655 chelation therapy Methods 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 11
- 230000002519 immonomodulatory effect Effects 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 230000002861 ventricular Effects 0.000 claims description 9
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 8
- 239000002934 diuretic Substances 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001051 dimercaprol Drugs 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 229960003105 metformin Drugs 0.000 claims description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 238000002616 plasmapheresis Methods 0.000 claims description 3
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 239000000523 sample Substances 0.000 description 72
- 201000010099 disease Diseases 0.000 description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 49
- 238000004458 analytical method Methods 0.000 description 45
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 31
- 229910052791 calcium Inorganic materials 0.000 description 31
- 239000011575 calcium Substances 0.000 description 31
- 201000001320 Atherosclerosis Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 23
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 23
- 108010074051 C-Reactive Protein Proteins 0.000 description 22
- 239000000090 biomarker Substances 0.000 description 22
- 230000002526 effect on cardiovascular system Effects 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 21
- 230000008859 change Effects 0.000 description 20
- 230000034994 death Effects 0.000 description 20
- 231100000517 death Toxicity 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 18
- 239000000902 placebo Substances 0.000 description 18
- 230000000391 smoking effect Effects 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 208000010125 myocardial infarction Diseases 0.000 description 12
- 208000017169 kidney disease Diseases 0.000 description 11
- 206010052337 Diastolic dysfunction Diseases 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000002586 coronary angiography Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000010197 meta-analysis Methods 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000007211 cardiovascular event Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 6
- 238000001325 log-rank test Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 208000028399 Critical Illness Diseases 0.000 description 5
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 5
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000000557 podocyte Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960000672 rosuvastatin Drugs 0.000 description 5
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 4
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 4
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 4
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 238000007675 cardiac surgery Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- -1 devices Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 4
- 229960000815 ezetimibe Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000007427 paired t-test Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 201000011461 pre-eclampsia Diseases 0.000 description 4
- 230000005586 smoking cessation Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 description 3
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 208000037806 kidney injury Diseases 0.000 description 3
- 238000011551 log transformation method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000272186 Falco columbarius Species 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 102220544695 Urokinase plasminogen activator surface receptor_L317P_mutation Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000002715 bioenergetic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012562 intraclass correlation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000013160 medical therapy Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940074790 simvastatin and ezetimibe Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102100030762 Apolipoprotein L1 Human genes 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000018663 Central Nervous System Viral disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 101100346152 Drosophila melanogaster modSP gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 101150013552 LDLR gene Proteins 0.000 description 1
- 101150030891 MRAS gene Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150094724 PCSK9 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 102220555610 Urokinase plasminogen activator surface receptor_K220R_mutation Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 206010003668 atrial tachycardia Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000117 blood based biomarker Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000007475 c-index Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- WYYQVWLEPYFFLP-UHFFFAOYSA-K chromium(3+);triacetate Chemical compound [Cr+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WYYQVWLEPYFFLP-UHFFFAOYSA-K 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940092923 livalo Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000730 protein immunoprecipitation Methods 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000024155 regulation of cell adhesion Effects 0.000 description 1
- 230000012760 regulation of cell migration Effects 0.000 description 1
- 201000011303 renal artery atheroma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013432 robust analysis Methods 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- soluble urokinase plasminogen activator receptor sertrapeptide plasminogen activator receptor
- the disclosure provides a method for treating cardiovascular disease in a subject, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from cardiovascular disease; (b) performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level; or (c) stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 3 ng/mL), whereby the cardiovascular disease in the subject is treated.
- the cardiovascular disease is coronary artery disease (CAD), such as triple-vessel disease (TVD).
- stenting is performed by percutaneous coronary intervention (PCI).
- the disclosure also provides a method of treating stable cardiovascular disease or preventing cardiovascular disease in a subject, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from stable cardiovascular disease or a subject at high risk for cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3.0 ng/mL); and (c) administering a statin, an immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented.
- a threshold level e.g., about 3.0 ng/mL
- administering a statin, an immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented.
- the subject suffers from stable cardiovascular disease.
- the cardiovascular disease is coronary artery disease.
- the subject is at high risk for cardiovascular disease and the method prevents cardiovascular disease.
- the method comprises administering a statin to the subject.
- the method comprises administering an immunomodulatory therapy to the subject, such as methotrexate, metformin, cananikumab, and a mineralocorticoid receptor antagonist.
- the method comprises administering an anti-suPAR therapy to the subject, such as a monoclonal antibody that specifically binds to suPAR, or plasmapheresis using suPAR-specific cartridges.
- the disclosure also provides a method of preventing or treating cardiovascular disease using chelation therapy, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL) and (c) administering chelation therapy to the subject in the suPAR level is above the threshold level, thereby preventing cardiovascular disease in the subject.
- the chelation therapy comprises administering ethylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid, or dimercaprol to the subject.
- EDTA ethylenediaminetetraacetic acid
- dimercaptosuccinic acid dimercaprol
- the disclosure also provides a method of treating congestive heart failure in a subject with concomitant kidney dysfunction, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from congestive heart failure with concomitant kidney dysfunction; (b) performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than the threshold level; or (c) performing single organ heart transplantation if the level of suPAR in the sample is less than the threshold level, whereby the congestive heart failure in the subject is treated.
- the mechanical circulatory support is a left ventricular assist device, a right ventricular assist device, or a total artificial heart.
- the disclosure also provides a method of treating kidney dysfunction in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from kidney dysfunction; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a treatment for kidney dysfunction to the subject, whereby the kidney dysfunction is treated in the subject.
- suPAR soluble urokinase plasminogen activator receptor
- the disclosure also provides a method of treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from HFpEF; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a HFpEF treatment to the subject, such as mineralocorticoid antagonists, whereby HFpEF is treated in the subject.
- a HFpEF treatment such as mineralocorticoid antagonists
- the sample is blood or urine
- the level of suPAR is determined or measured by immunoassay, immunoprecipitation, Western blot, flow cytometry, or protein microarray.
- FIGS. 1A-1C are graphs showing the relationship between suPAR levels and the outcomes all-cause death ( 1 A), cardiovascular death ( 1 B), and hospitalization for heart failure ( 1 C). Survival curves are stratified by suPAR quartiles.
- FIG. 3 is a Manhattan plot of results from the GWAS of 3,244 participants.
- the top signal detected at the PLAUR locus is SNP rs4760 which encodes a nonsynonymous variant.
- Other significant signals are detected at the PLAU, LY75, and ST3GAL4 loci.
- FIG. 4 shows that suPAR levels are stable post-myocardial infarction.
- High-sensitivity C-reactive (hsCRP), suPAR, and troponin were measured serially in 296 consecutive patients presenting with an ST-elevation myocardial infarction.
- FIGS. 5A and 5B are graphs showing survival of patients stratified by statin therapy in patients with median suPAR levels ⁇ 3000 pg/mL ( 5 A) and patients with median suPAR levels >3000 pg/mL ( 5 B).
- administering refers to the act of giving a drug, prodrug, therapeutic, or other agent to a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs.
- routes of administration to the human body can be through space under the arachnoid membrane of the brain or spinal cord (intrathecal), the eyes (ophthalmic), mouth (oral), skin (topical or transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
- biomarker and “biological marker” are used synonymously herein and refer to a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.
- a biomarker may comprise a substance whose detection indicates a particular disease state (e.g., the presence of an antibody may indicate an infection). More specifically, a biomarker may indicate a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a particular treatment.
- biomarkers range widely and include, but are not limited to, molecular biomarkers (e.g., nucleic acids, gene products, and proteins), physiologic biomarkers (e.g., blood pressure or blood flow), or anatomic biomarkers (e.g., the structure of a particular organ).
- molecular biomarkers e.g., nucleic acids, gene products, and proteins
- physiologic biomarkers e.g., blood pressure or blood flow
- anatomic biomarkers e.g., the structure of a particular organ.
- CVD cardiovascular disease
- vasculature e.g., veins and arteries
- diseases and conditions including, but not limited to arteriosclerosis, atherosclerosis, myocardial infarction, acute coronary syndrome, angina, congestive heart failure, aortic aneurysm, aortic dissection, iliac or femoral aneurysm, pulmonary embolism, primary hypertension, gestational hypertension, pre-eclampsia, atrial fibrillation, stroke, transient ischemic attack, systolic dysfunction, diastolic dysfunction, myocarditis, atrial tachycardia, ventricular fibrillation, endocarditis, arteriopathy, vasculitis, atherosclerotic plaque, vulnerable plaque, acute coronary syndrome, acute ischemic attack, sudden cardiac death, peripheral
- cardiovascular event refers to the manifestation of an adverse condition in a subject brought on by cardiovascular disease, such as sudden cardiac death or acute coronary syndromes including, but not limited to, myocardial infarction, gestational hypertension, pre-eclampsia, unstable angina, aneurysm, or stroke.
- cardiovascular disease can be used interchangeably herein with the term “cardiovascular complication.” While a cardiovascular event can be an acute condition, it can also represent the worsening of a previously detected condition to a point where it represents a significant threat to the health of the subject, such as the enlargement of a previously known aneurysm or the increase of hypertension to life threatening levels.
- coronary artery disease refers to the narrowing or blockage of the coronary arteries due primarily to atherosclerosis (i.e., buildup of cholesterol and fatty deposits (“plaques”) on the inner walls of the arteries).
- the narrowing or blockage of the coronary arteries results in reduction of blood flow to the heart muscle.
- Coronary artery disease also known as “ischemic heart disease (IHD)”
- IHD ischemic heart disease
- diagnosis encompasses determining the nature of disease in a subject, as well as determining the severity and probable outcome of disease or episode of disease and/or prospect of recovery (prognosis). “Diagnosis” can also encompass diagnosis in the context of rational therapy, in which the diagnosis guides therapy, including initial selection of therapy, modification of therapy (e.g., adjustment of dose and/or dosage regimen or lifestyle change recommendations), and the like.
- heart failure refers to a condition in which the heart cannot pump blood efficiently to the rest of the body.
- Heart failure may be due to damage to the heart or narrowing of the arteries due to infarction, cardiomyopathy (primary or secondary), hypertension, coronary artery disease, valve disease, birth defects, or infection.
- Heart failure can further be described as chronic, congestive, acute, decompensated, systolic or diastolic.
- the New York Heart Association (NYHA) classification describes the severity of the disease based on functional capacity of the patient; NYHA class can progress and/or regress based on treatment or lack of response to treatment.
- “increased severity” of cardiovascular disease refers to the worsening of disease as indicated by increased NYHA classification, to, for example, Class III or Class IV
- “reduced severity” of cardiovascular disease refers to an improvement of the disease as indicated by reduced NYHA classification, from, for example, class III or IV to class II or I.
- ejection fraction refers to the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a subject's cardiac function.
- Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction.
- Right ventricular ejection fraction (RVEF) is the measurement of how much blood is being pumped out of the right side of the heart to the lungs for oxygen.
- ejection fraction refers to left ventricular ejection fraction.
- HFpEF heart failure with preserved ejection fraction
- HFrEF heart failure with reduced ejection fraction
- the terms “individual,” “host,” “subject,” and “patient” are used interchangeably herein and refer to any vertebrate, including, but not limited to, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (for example, a monkey, such as a cynomolgus monkey, chimpanzee, etc.) and a human).
- a mammal e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse
- a non-human primate for example, a monkey, such as a cynomolgus monkey, chimpanzee, etc.
- the subject is a human.
- the terms “increased,” “increase,” and “elevated” may be used interchangeably herein and refer to an amount or a concentration in a sample that is higher or greater than a predetermined level or range, such as a typical or normal level found in a control group or control sample, or is higher or greater than another reference level or range (e.g., earlier or baseline sample).
- the terms “decreased,” “decrease,” “lowered,” and “reduced” may be used interchangeably herein and refer to an amount or a concentration in a test sample that is lower or less than a predetermined level or range, such as a typical or normal level found in a control group or control sample, or is lower or less than another reference level or range (e.g., earlier or baseline sample).
- altered refers to an amount or a concentration in a sample that is altered (increased or decreased) over a predetermined level or range, such as a typical or normal level found in a control group or control sample, or over another reference level or range (e.g., earlier or baseline sample).
- prevent refers to completely or partially inhibiting onset of a disease or symptom thereof.
- a “prophylactically effective amount” of a particular compound, drug, or agent refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset).
- the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect.
- the effect is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptom attributable to the disease.
- a “therapeutically effective amount” of a particular compound, drug, or agent refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result.
- a therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of a subject.
- the present disclosure is predicated, at least in part, on the discovery that the levels of soluble urokinase plasminogen activator receptor (suPAR) levels in blood are strongly predictive of several outcomes in cardiovascular disease patient populations, including death, myocardial infarction, heart failure and kidney disease, beyond traditionally measured markers of risk; and reflect a pathway of disease not accounted for by traditional testing. It has also been found that increased suPAR levels are predictive of kidney dysfunction and heart failure with preserved ejection fraction (HFpEF).
- HFpEF preserved ejection fraction
- measuring suPAR levels in hospitalized patients prior to discharge may help distinguish patients requiring earlier follow-up (e.g., patients with high suPAR) and/or initiation of telehealth monitoring strategies from patients who will benefit from delayed follow-up (e.g., patients with low suPAR).
- patients requiring earlier follow-up e.g., patients with high suPAR
- suPAR as a biomarker in CVD patients will allow clinicians to better allocate resources and reduce hospitalization, thus improving the cost effectiveness of care.
- Soluble urokinase plasminogen activator receptor (suPAR) (NCBI Accession No. AAK31795) is the circulating form of a glycosyl-phosphatidylinositol-anchored three-domain membrane protein that is expressed on a variety of cells, including immunologically active cells, endothelial cells, podocytes, keratinocytes, fibroblasts, smooth muscle cells, megakaryocytes, and certain tumor cells (Thuno et al., Disease Markers, 27: 157-172 (2009); Wei et al., Nat Med, 14: 55-63 (2008); and Huai et al., Science, 311: 656-659 (2006)).
- Both the circulating and membrane-bound forms of suPAR are directly involved in the regulation of cell adhesion and migration through binding of integrins (Thuno et al., supra).
- the circulating form is produced by cleavage of membrane-bound urokinase-type plasminogen activator receptor and is readily detected in plasma, serum, urine, and other bodily fluids.
- Increased activation of the immune system leads to increased serum suPAR levels, which has been documented in several pathological conditions, including paroxysmal nocturnal hemoglobinuria, human immunodeficiency virus type 1 (HIV-1) infection, malaria, pneumococcal and Streptococcus pneumonia bacteraemia, sepsis, bacterial and viral CNS infection, active tuberculosis (TB) and also in various types of solid tumors (e.g., non-small cell lung cancer, breast, colorectal, prostate, and ovarian cancer) (Thuno et al., supra).
- HAV-1 human immunodeficiency virus type 1
- T active tuberculosis
- solid tumors e.g., non-small cell lung cancer, breast, colorectal, prostate, and ovarian cancer
- suPAR also has been implicated in the pathogenesis of kidney disease, specifically focal segmental glomerulosclerosis and diabetic nephropathy, through interference with podocyte migration and apoptosis (Hayek et al., N Engl J Med, 373: 1916-1925 (2015)). Furthermore, high blood concentrations of suPAR independently predict high mortality in both patients and healthy individuals (Eugen-Olsen et al., Int J Tuberc Lung Dis, 6: 686-692 (2002)).
- sample and “biological sample” are used interchangeably herein and refer to bodily fluids such as blood-related samples (e.g., whole blood, serum, plasma, and other blood-derived samples), urine, cerebral spinal fluid, bronchoalveolar lavage, and the like.
- blood-related samples e.g., whole blood, serum, plasma, and other blood-derived samples
- urine e.g., cerebral spinal fluid
- bronchoalveolar lavage e.g., bronchoalveolar lavage, and the like.
- tissue sample e.g., A biological sample may be fresh or stored (e.g., blood or blood fraction stored in a blood bank).
- the biological sample may be a bodily fluid expressly obtained for the methods described herein or a bodily fluid obtained for another purpose which can be sub-sampled for the methods of this disclosure.
- the biological sample is whole blood.
- Whole blood may be obtained from the subject using standard clinical procedures.
- the biological sample is plasma.
- Plasma may be obtained from whole blood samples by centrifugation of anti-coagulated blood, which provides a buffy coat of white cell components and a supernatant of the plasma.
- the biological sample may be serum. Serum may be obtained by centrifugation of whole blood samples that have been collected in tubes that are free of anti-coagulant. The blood is permitted to clot prior to centrifugation. The yellowish-reddish fluid that is obtained by centrifugation is the serum.
- the sample may be urine.
- the sample may be pretreated as necessary by dilution in an appropriate buffer solution, heparinized, concentrated if desired, or fractionated by any number of methods, including but not limited to ultracentrifugation, fractionation by fast performance liquid chromatography (FPLC), or precipitation of apolipoprotein B containing-proteins with dextran sulfate or other methods.
- FPLC fast performance liquid chromatography
- Methods well-known in the art for collecting, handling and processing urine, blood, serum and plasma, and other body fluids may be used in the practice of the present disclosure.
- the level of suPAR protein may be measured, determined, and/or quantified using any suitable method for protein detection and/or quantification known in the art.
- suitable methods include, but are not limited to, immunoassays (e.g., enzyme linked-immunosorbent assay (ELISA)), protein immunoprecipitation, immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, protein immunostaining, electrophoresis analysis, competitive binding assays, functional protein assays, protein microarray, or chromatography or spectrometry methods (e.g., high-performance liquid chromatography (HPLC), mass spectrometry, liquid chromatography-mass spectrometry (LC/MS), capillary electrophoresis (CE)-MS, or any separating front end coupled with MS detection and quantification) (see, e.g., Salvatore Sechi, Quantitative Proteomics by Mass Spectrometry (Methods in Molecular Biology) 2nd
- suPAR may be present in the sample at low levels that may not be efficiently detected using conventional methods.
- the suPAR protein may be detected using ultrasensitive methodologies and devices specifically designed for detecting low abundant proteins in a sample.
- ultrasensitive methodologies and devices include, but are not limited to, microfluidic analytical systems (such as those described in, e.g., Martel, J. M. and Toner, M., Annu Rev Biomed Eng., 16: 371-96 (2014); Martel et al., Annu Rev Biomed Eng., 16: 371-96 (2014); Malhotra et al., Anal. Chem., 84, 6249-6255 (2012); and U.S.
- Patent Application Publication 2018/0161775 A1 ultra-sensitive ELISA assays (see, e.g., Schubert et al., Scientific Reports, 5: Article number: 11034 (2015)), and nanoparticle-based systems (see, e.g., Li et al., Biosensors and Bioelectronics, 68: 626-632 (2015)).
- the methods described herein involves comparing the levels of suPAR in a patient sample with a predetermined value or cutoff.
- predetermined cutoff refers to an assay cutoff value that is used to assess diagnostic, prognostic, or therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the predetermined cutoff/value already has been linked or associated with various clinical parameters (e.g., presence of disease, stage of disease, severity of disease, progression, non-progression, improvement of disease, etc.).
- the disclosure provides exemplary predetermined levels and reference levels. However, it is well-known that cutoff values may vary depending on the nature of the detection method or assay. Whereas the precise value of the predetermined cutoff/value may vary between assays, the correlations as described herein should be generally applicable.
- the predetermined value can take a variety of forms.
- the predetermined value can be single cut-off value, such as a median or mean.
- the predetermined value can be established based upon comparative groups, such as where the risk of coronary artery disease in one defined group is double the risk in another defined group.
- the predetermined value can be a range, for example, where the tested population is divided equally (or unequally) into groups, such as-a low-risk group, a medium-risk group, and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk and the highest quadrant being individuals with the highest risk.
- the predetermined value can depend upon the particular population selected. For example, an apparently healthy population will have a different normal range of biomarker expression levels than will a population comprised of patients with symptoms of cardiovascular disease or heart failure. In another embodiment, a population comprised of patients with congestive heart failure will have a different range of suPAR expression levels than will a population of patients with stable cardiovascular disease. Accordingly, the predetermined values selected may take into account the disease category in which an individual is grouped. Appropriate ranges and categories can be selected by those of ordinary skill in the art using routine methods. In some embodiments, an algorithm may be used to determine a predetermined value or threshold for decision making.
- Such an algorithm may consider a variety of factors, including, for example, (i) the age of the subject (e.g., higher threshold at higher age), (ii) renal function (e.g., lower threshold with better renal function because the kidneys are actively clearing suPAR), and (iii) gender (e.g., about 3 ng/mL suPAR (male) and about 4 ng/mL suPAR (female)).
- age of the subject e.g., higher threshold at higher age
- renal function e.g., lower threshold with better renal function because the kidneys are actively clearing suPAR
- gender e.g., about 3 ng/mL suPAR (male) and about 4 ng/mL suPAR (female)
- a “normal” or “baseline” level of suPAR protein in a sample obtained from a subject will vary depending on a variety of factors, such as the subject's gender, age, overall health, the sample type (e.g., whole blood, serum, etc.), the suPAR isoform measured, and the assay used for measuring suPAR levels.
- a normal level of suPAR in human blood is from about 2.5 ng/mL to about 5.0 ng/mL (e.g., about 2.5 ng/mL, about 3.0 ng/mL, about 3.5 ng/mL, about 4.0 ng/mL, about 4.5 ng/mL, or about 5.0 ng/mL).
- a normal level of suPAR in human blood is less than 3.0 ng/mL (e.g., 2.9 ng/mL, 2.8 ng/mL, 2.7 ng/mL, 2.6 ng/mL, 2.5 ng/mL, 2.4 ng/mL, 2.3 ng/mL, 2.2 ng/mL, 2.1 ng/mL, 2.0 ng/mL, 1.9 ng/mL, 1.8 ng/mL, 1.7 ng/mL, 1.6 ng/mL, 1.5 ng/mL, 1.4 ng/mL, 1.3 ng/mL, 1.2 ng/mL, 1.1 ng/mL, 1.0 ng/mL, 0.9 ng/mL, 0.8 ng/mL, 0.7 ng/mL, 0.6 ng/mL, 0.5 ng/mL, 0.4 ng/mL, 0.3 ng/mL, 0.2 ng/mL, 0.1
- the normal level of suPAR in men is about 2.1 ng/mL and in women is about 2.5 ng/mL.
- a suPAR level that is higher than the normal range may be indicative of a pathological condition, such as kidney disease or cardiovascular disease.
- certain disease states may be indicated by blood suPAR protein levels greater than any suPAR level within the normal range of 2.5 ng/mL to about 5.0 ng/mL.
- certain disease states may be indicated by blood suPAR protein levels greater than about 2.5 ng/mL (e.g., about 2.75 ng/mL, about 2.8 ng/mL, about 2.9 ng/mL, about 2.95 ng/mL, or greater), preferably greater than about 3.0 ng/mL (e.g., 3.5 ng/mL, 4.0 ng/mL, 4.5 ng/mL, or greater), and more preferably greater than about 5.0 ng/mL (e.g., 5.5 ng/mL, 6.0 ng/mL, 6.5 ng/mL, 7.0 ng/mL, 7.5 ng/mL, 8.0 ng/mL, 8.5 ng/mL, 9.0 ng/mL, 9.5 ng/mL, 10.0 ng/mL, 10.5 ng/mL, 15 ng/mL, 20 ng/mL, or greater). Furthermore, in patient populations which already exhibit high suPAR levels (e.g
- the level of suPAR protein may be considered “elevated” if the level measured is above a predetermined threshold level.
- a threshold level can be set to the 90th-percentile or to the 95th-percentile of a healthy control population.
- the threshold level is established at the 95th-percentile of a healthy control population.
- a particular therapeutic decision or risk assessment for a subject suffering from, or at risk of suffering from, cardiovascular disease is indicated when the level of suPAR is at least 2-fold greater (e.g., 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50-fold, or greater) than a predetermined normal level of suPAR.
- the disclosure provides a method for treating cardiovascular disease in a subject, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from cardiovascular disease; (b) performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL); or (c) stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 3 ng/ml), whereby the cardiovascular disease in the subject is treated.
- the cardiovascular disease is coronary artery disease (as defined above).
- the coronary artery disease may be of any stage or severity.
- Coronary artery disease severity typically is determined by a number of factors, including but not limited to, left ventricular function, anatomic extent and severity of coronary atherosclerosis (e.g., the number of vessels with significant obstructive coronary disease), severity of ischemia, tempo and severity of angina and/or the presence of recent plaque rupture, and the patient's general health and noncoronary comorbid conditions.
- the subject suffers from coronary artery disease with significant obstructive coronary disease in one, two, three, or four coronary blood vessels (e.g., single-, double-, triple-vessel, or quadruple-vessel disease).
- the subject suffers from triple-vessel disease (TVD).
- TDD triple-vessel disease
- the method involves performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL).
- a threshold level e.g., about 3 ng/mL.
- CABG coronary artery bypass graft
- CABG is often indicated when coronary arteries have a 50 to 99 percent obstruction.
- the obstruction being bypassed is typically due to arteriosclerosis, atherosclerosis, or both.
- the terms “single bypass,” “double bypass,” “triple bypass,” “quadruple bypass,” and “quintuple bypass” refer to the number of coronary arteries bypassed in the procedure.
- a double bypass means two coronary arteries are bypassed (e.g., the left anterior descending (LAD) coronary artery and right coronary artery (RCA)); a triple bypass means three vessels are bypassed (e.g., LAD, RCA and left circumflex artery (LCX)); a quadruple bypass means four vessels are bypassed (e.g., LAD, RCA, LCX and first diagonal artery of the LAD), etc.
- Left main coronary artery obstruction requires two bypasses, one to the LAD and one to the LCX.
- the method involves stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than a threshold level (e.g., about 3 ng/mL).
- a threshold level e.g., about 3 ng/mL.
- stenting refers to the placement of a stent into a coronary artery.
- a “stent” is a tubular support placed temporarily inside a blood vessel, canal, or duct to aid healing or relieve an obstruction. Stenting is typically performed by percutaneous coronary intervention (PCI), which is a non-surgical procedure used to treat narrowing (stenosis) of coronary arteries.
- PCI percutaneous coronary intervention
- PCI also known as “coronary angioplasty,” requires the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into coronary arteries (referred to as “cardiac catheterization”).
- PCI may be used to relieve symptoms of coronary artery disease or to reduce heart damage during or after a heart attack.
- the most prevalent stents used in the art are drug-eluting metal stents (DES), which have shown some benefits relative to bare metal stents with respect to early incidences of restenosis (Kang et al., J Am Coll Cardiol., 62(2): B251 (2014); Bosiers et al., Vasc Health Risk Manag., 4(43): 553 (2008)).
- the disclosure provides a method of treating stable cardiovascular disease or preventing cardiovascular disease in a subject, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from stable cardiovascular disease or a subject at high risk for cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 2.5 ng/mL); and (c) administering a statin, an immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented.
- a threshold level e.g., about 2.5 ng/mL
- a cardiovascular disease may be considered “stable” if a patient is asymptomatic, or when symptoms, if present, are manageable with either medical or revascularization therapy.
- the cardiovascular disease is coronary artery disease.
- “Stable coronary artery disease” is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischemia or hypoxia, which are usually inducible by exercise, emotion or other stress and are reproducible, but such episodes may also occur spontaneously. Such episodes of ischemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris).
- SCAD also includes the stabilized, often asymptomatic, phases that follow an acute coronary syndrome (ACS) (2013 ESC Guidelines on the Management of Stable Coronary Artery Disease, The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology, European Heart Journal, 34, 2949-3003(2013)).
- ACS acute coronary syndrome
- the subject is at high risk for developing cardiovascular disease, and the method prevents cardiovascular disease in the subject.
- a subject is considered “high risk” for developing cardiovascular disease, such as coronary artery disease, as a result of various conditions and behaviors including, but not limited to, high blood pressure, high cholesterol, diabetes, obesity, physical inactivity, unhealthy diet, smoking, and heavy alcohol consumption.
- a family history of cardiovascular disease, as well as age, race, and gender also are risk factors for heart disease.
- the term “high risk,” as used herein, is defined as greater than a 25% chance, preferably greater than or equal to a 30% chance, and more preferably greater than a 35% chance of a subject developing cardiovascular disease.
- low risk is defined as less than or equal to a 10% chance, preferably less than a 5% chance, and more preferably less than a 2% chance of a subject developing cardiovascular disease.
- moderate risk is defined as greater than a 10% and less than a 30% chance of a subject developing cardiovascular disease.
- risk assessment refers to the evaluation of factors including biomarkers, to predict the risk of occurrence of future events in a subject including disease onset or disease progression, so that treatment decisions regarding the subject may be made on a more informed basis.
- the method involves determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 2.5 ng/mL; as described herein), and administering a statin, and immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented.
- a threshold level e.g., about 2.5 ng/mL; as described herein
- Statins are a class of lipid-lowering drugs which inhibit HMG-CoA reductase and block the pathway for synthesizing cholesterol in the liver.
- Statins include, but are not limited to, atorvastatin (LIPITOR), fluvastatin (LESCOL), lovastatin (ALTOPREV), pitavastatin (LIVALO), pravastatin (PRAVACHOL), rosuvastatin (CRESTOR), and simvastatin (ZOCOR).
- atorvastatin LIPITOR
- fluvastatin LESCOL
- lovastatin ALTOPREV
- LIVALO pitavastatin
- PRAVACHOL pravastatin
- ZOCOR simvastatin
- the terms “immunomodulatory therapy” and “immunotherapy” are used interchangeably herein and refer to the treatment or prevention of a disease or condition by inducing, enhancing, suppressing or otherwise modifying an immune response. Immune dysregulation and inflammation contribute to the development of atherosclerotic plaques and their progression to acute coronary syndromes.
- hsCRP high sensitivity C-reactive protein
- Target-specific therapies directed at pro-inflammatory cytokines such as IL-1 ⁇ , IL-6, TNF ⁇ , and CCL2 have demonstrated slowing in the progression of atherosclerosis in animal models and improved cardiovascular outcomes in human subjects (Khambhati et al., Atherosclerosis, 276: 1-9 (2018)).
- the monoclonal antibody canakinumab directly targets and neutralizes IL-1 ⁇ , and was recently shown to be associated with reduced risk of adverse cardiovascular events compared to placebo in a randomized, placebo-controlled trial (Ridker et al., Am. Heart J., 162: 597-605 (2011); and Ridker et al., N Engl. J. Med., 377: 1119-1131 (2017)).
- Several other therapies including colchicine, methotrexate, metformin, mineralocorticoid receptor antagonists (e.g., spironolactone or eplerenone), and leukotriene inhibitors demonstrate potential for lowering cardiovascular risk through immunomodulation.
- the method comprises administering an anti-suPAR therapy to the subject, such as a monoclonal antibody that specifically binds to suPAR (as described in, e.g., Rabanni et al., Neoplasia, 12(10): 778-788 (2010)), or plasmapheresis using suPAR-specific cartridges.
- an anti-suPAR therapy such as a monoclonal antibody that specifically binds to suPAR (as described in, e.g., Rabanni et al., Neoplasia, 12(10): 778-788 (2010)), or plasmapheresis using suPAR-specific cartridges.
- the disclosure provides a method of treating or preventing cardiovascular disease in a subject using chelation therapy, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject at risk of cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL); and (c) administering a chelation therapy to the subject, thereby treating or preventing cardiovascular disease in the subject.
- a threshold level e.g., about 3 ng/mL
- chelation therapy refers to a method for removing heavy metals, such as mercury or lead, from blood. Practitioners have used ethylene diamine tetraacetic acid (EDTA-based) chelation therapy to treat complications of atherosclerosis in diabetes for decades, but without robust evidence of its efficacy. In 2013, the Trial to Assess Chelation Therapy (TACT) study exhibited clinical benefit of an EDTA-based infusion regimen (40 infusions plus high-dose vitamins) in patients (>50 years of age) who had a prior myocardial infarction (MI) (Escolar et al., Circ Cardiovasc Qual Outcomes, 7: 15-24 (2014)).
- the chelation therapy may be performed using routine methods known in the art, and may comprise administering ethylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid, or dimercaprol to the subject.
- EDTA ethylenediaminetetraacetic acid
- dimercaptosuccinic acid dimercaprol
- the disclosure provides a method of treating congestive heart failure in a subject with concomitant kidney dysfunction, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from congestive heart failure with concomitant kidney dysfunction; (b) performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 5 ng/mL); or (c) performing single organ heart transplantation on the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 5 ng/mL), whereby the congestive heart failure in the subject is treated.
- a threshold level e.g., about 5 ng/mL
- the threshold level e.g., about 5 ng/mL
- HF congestive heart failure
- CKD chronic kidney disease
- the method involves performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 5 ng/mL) or performing single organ heart transplantation on the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 5 ng/mL).
- a threshold level e.g., about 5 ng/mL
- the threshold level e.g., about 5 ng/mL
- heart transplant and “cardiac transplant” are synonymous and refer to a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease when other medical or surgical treatments have failed.
- Heart transplants are most commonly performed by obtaining a functioning heart, with or without one or both lungs, from a recently deceased organ donor (brain death is the standard) and implanting the heart and one or both lungs into the patient.
- the recipient's own heart is either removed and replaced with the donor heart (i.e., an “orthotopic” transplant procedure) or, much less commonly, the recipient's diseased heart is left in place to support the donor heart (i.e., a “heterotopic” or “piggyback” transplant procedure).
- kidney transplant refers to a surgical transplant procedure performed on patients with end-stage renal disease in which a healthy kidney from a live or deceased donor is placed into the diseased patient. More than 20,000 kidney transplants are performed annually in the U.S.
- MCS mechanical circulatory support
- an MCS device refers to a device that either supplements or replaces the action of the failing heart or lungs.
- an MCS device is provided to heart failure patients who experience refractory cardiogenic shock, which is defined as cardiac and circulatory failure resulting in organ hypoperfusion.
- refractory cardiogenic shock which is defined as cardiac and circulatory failure resulting in organ hypoperfusion.
- a variety of MCS devices are known in the art and can be used in connection with the disclosed methods (see, e.g., G. C. Stewart and M. M.
- Suitable MCS devices include, for example, left or right ventricular assist devices (e.g., THORATEC® pVAD, BVS5000, AB5000, CENTRIMAGTM, TANDEMHEART®, or IMPELLA®), an intra-aortic balloon pump (IABP), extra-corporeal membrane oxygenation (ECMO), and a total artificial heart (e.g., Abiomed TAH, CardioWest TAH).
- left or right ventricular assist devices e.g., THORATEC® pVAD, BVS5000, AB5000, CENTRIMAGTM, TANDEMHEART®, or IMPELLA®
- IABP intra-aortic balloon pump
- ECMO extra-corporeal membrane oxygenation
- a total artificial heart e.g., Abiomed TAH, CardioWest TAH.
- the disclosure also provides a method of treating kidney dysfunction in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from kidney dysfunction; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a treatment for kidney dysfunction to the subject, whereby the kidney dysfunction is treated in the subject.
- suPAR soluble urokinase plasminogen activator receptor
- Acute kidney injury occurs in 2 to 5% of hospitalized adults and has a major effect on morbidity and health care utilization (Bellomo et al., Lancet, 380: 756-66 (2012); Rewa O, Bagshaw S M, Nat Rev Nephrol, 10: 193-207 (2014); Lameire et al., Lancet, 382: 170-9 (2013); and Pakula A M, Skinner R A., J Intensive Care Med, 31: 319-24 (2016)).
- Inflammation and oxidative stress are central components of the pathogenesis of acute kidney injury, implicating multiple subtypes of immune cells (Tran et al., Nature 2016; 531: 528-32; and Rabb et al., J Am Soc Nephrol 2016; 27: 371-9).
- Evidence of a pathway linking the bone marrow to kidney injury has emerged, involving suPAR (Hayek et al., Nat Med, 23: 945-53 (2017); and Hayek et al., N. Engl. J. Med., 382: 416-26 (2020); doi: 10.1056/NEJMoa1911481).
- kidney dysfunction treated by the disclosed method may also be chronic kidney disease (CKD).
- Chronic kidney disease affects close to 50 million people in the United States alone, with a growing disease burden over the past 15 years and 58% increase in attributable deaths since 2002 (Webster et al., Lancet, 389(10075): 1238-52 (2017); Bowe et al., JAMA Netw Open, 1(7): e184412 (2016); and Saran et al., Am J Kidney Dis.; 73(3S1): A7-A8 (2019)).
- CKD chronic kidney disease
- CVD cardiovascular disease
- SuPAR is released by Gr-1 lo immature myeloid cells in response to pro-inflammatory stimuli to the bone marrow, and circulates to the kidneys where it binds to ⁇ v ⁇ 3 integrin expressed by podocytes (Wei et al., Nat Med. 2008; 14(1):55-63, Hahm et al., Nat Med. 2017; 23(1):100-6, and Wei et al., J Clin Invest. 2019; 129(5):1946-59).
- Pathologic integrin activation by suPAR induces podocyte cytoskeletal restructuring, autophagy, and effacement leading to proteinuria and chronic kidney dysfunction (Wei et al., Nat Med.
- treatment regimens for kidney dysfunction can be used.
- suitable treatment regimens or therapeutics include, for example, statins (described above) diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, beta blockers, an anti-suPAR therapy (described above), a kidney transplant, dialysis, or a combination of any of the foregoing.
- the disclosure also provides a method of treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from HFpEF; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a HFpEF treatment to the subject, whereby HFpEF is treated in the subject.
- suPAR soluble urokinase plasminogen activator receptor
- HFpEF heart failure with preserved ejection
- MRA mineralocorticoid receptor antagonists
- HFpEF a heterogeneous disease with various comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency that drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction (Shah et al., Circulation. 2016; 134(1):73-90; and Paulus W J, Tschope C. J Am Coll Cardiol. 2013; 62(4):263-71).
- Blood-based biomarkers have been proposed as a method to accurately characterize HFpEF phenotypes and identify patients that would benefit from specific therapies (Shah et al., supra; Paulus and Tschope, supra; and Myhre et al., Circ Heart Fail.
- suPAR plays a known pathogenic role in kidney disease, which is a common co-morbid condition in patients with HFpEF. Experiments described in detail below show that outcomes in HFpEF are tightly linked to suPAR levels.
- HFpEF HFpEF
- Treatment of HFpEF is largely governed by management of associated conditions and symptoms. Any number or variety of treatment regimens can be used, including any treatment that reduces the risk of developing HFpEF. Risk for developing HFpEF is reduced when systolic and diastolic blood pressure is less than about 140/90 mm Hg, or less than about 130/80 mm Hg if the subject has diabetes or renal disease.
- suitable treatment regimens or therapeutics include, for example, mineralocorticoid receptor antagonists and diuretics (to treat volume overload). If diuretics are chosen, it will be appreciated that volume depletion should be avoided.
- Angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and beta blockers can be used to treat hypertension but may not alter clinical outcomes in HFpEF.
- ARBs Angiotensin receptor blockers
- ACE angiotensin converting enzyme
- calcium channel blockers calcium channel blockers
- beta blockers can be used to treat hypertension but may not alter clinical outcomes in HFpEF.
- diuretic-based antihypertensive therapy ACE inhibitors, beta-blockers, glycemic control, and/or an anti-suPAR therapy (described above) can be employed to prevent heart failure.
- Clinicians also can encourage lifestyle changes in patients at risk of developing HFpEF, such as, for example, weight loss, smoking cessation, regular exercise, and a healthy diet.
- the disclosure also provides a method to direct the post-hospital discharge care of patients admitted with, treated for, or at high risk of cardiovascular disease, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained prior to discharge; (b) setting up a post-discharge follow-up in clinic within two weeks, telehealth monitoring or home care if the suPAR level in the sample is greater than a threshold level (e.g., about 3 ng/mL for men, and about 4 ng/mL for women) or (c) arranging for routine follow-up post-discharge for suPAR levels below the threshold.
- a threshold level e.g., about 3 ng/mL for men, and about 4 ng/mL for women
- telehealth monitoring is a cardiac event monitor, digital sensors, automated blood pressure monitoring, or an impedance monitor.
- the disclosure provides methods of diagnosing a disease or condition that is associated with an increase in suPAR levels.
- the disclosure provides diagnosing a subject as suffering from such a disease or condition, which comprises (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suspected of suffering from the disease or condition, (b) comparing the amount of suPAR in the subject to a threshold level of suPAR if the level of suPAR in the sample is greater than a threshold level; and (c) detecting a level of suPAR in the subject that is greater than the threshold level; and (d) diagnosing the subject as suffering from the disease or condition.
- sucPAR soluble urokinase plasminogen activator receptor
- the disease or condition may be any disease or condition described herein, including, but not limited to, cardiovascular disease (CVD), kidney dysfunction (e.g., chronic kidney disease (CKD) or acute kidney injury), congestive heart failure, and heart failure with preserved ejection fraction (HFpEF).
- CVD cardiovascular disease
- kidney dysfunction e.g., chronic kidney disease (CKD) or acute kidney injury
- HFpEF heart failure with preserved ejection fraction
- Other diseases or conditions associated with increased levels of suPAR may be diagnosed in accordance with the methods described herein.
- suPAR is a strong biomarker of CVD risk and is associated with atherosclerosis.
- SuPAR outperformed hs-CRP, high sensitivity troponin I (hsTnI) and B-type natriuretic peptide (BNP) in predicting outcomes of 4,613 patients undergoing coronary angiography for suspected CVD, as shown in Table 1.
- Model 1 Risk factors only 0.663 (0.621, 0.704) — Model 2: RF and suPAR 0.721 (0.679, 0.763) 0.058 (0.027,0.090) Model 3: RF and hs-TnI 0.676 (0.632, 0.721) 0.014 ( ⁇ 0.001, 0.029) Model 4: RF and hs-CRP 0.682 (0.633, 0.731) 0.016 ( ⁇ 0.006, 0.038) Model 5: RF and BNP 0.705 (0.679-0.730) 0.023 (0.006-0.039)
- suPAR levels were measured in a mouse model of atherosclerosis induced by injecting a gain-of-function adeno-associated viral (AAV) vector encoding the atherogenic D377Y mutation of the PCSK9 gene (Maxwell et al., Proc Natl Acad Sci USA. 2005; 102(6):2069-74). Expression of D377Y-PCSK9 led to dramatic increases in LDL by accelerating the degradation of the LDL receptor. This model was chosen to minimize off-target effects and the immunologic impact of the commonly used apoE or LDLr knockout mouse models (Oppi et al., Front Cardiovasc Med. 2019; 6:46). It was found that suPAR levels were not increased in mice with induced atherosclerosis compared to controls ( FIG. 2 ), suggesting that high suPAR levels are unlikely to be simply a consequence of atherosclerotic disease.
- AAV gain-of-function adeno-associated viral
- MESA Multi-Ethnic Study of Atherosclerosis
- CVD events including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failure; therapeutic interventions for CVD; and mortality.
- Studies from MESA have provided key findings that have altered the practice of CV medicine such as the identification of CAC as a predictor of events and its clinical usefulness (Polonsky et al., JAMA. 2010; 303(16):1610-6; Detrano et al., N Engl J Med. 2008; 358(13):1336-45), and is the ideal cohort to characterize suPAR's role in the development of CVD in a multiethnic sample of the general population. suPAR will be measured in 5,784 samples from the MESA study.
- Plasma levels of suPAR will be measured using the Virogates ELISA kit (suPARnostic kit; Copenhagen, Denmark), which has a lower detection limit of 100 pg/mL and intra- and inter-assay variation of 2.75% and 9.17%, respectively, as determined by the assay manufacturer. Serum suPAR levels have shown stability extending up to 5 years in storage, and with repeated freeze-thaw. (82) All major publications on suPAR have used the suPARnostic assay (see, e.g., Diederichsen et al., Atherosclerosis. 2018; 271:245-51, Andersen et al., J Med Virol. 2008; 80(2):209-16, Botha et al., supra, and Sorensen et al., supra).
- suPAR has been compared to hs-CRP, hs-TnI and BNP in 4,613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank (Ko et al., supra), and suPAR has been found to be strongly predictive of outcomes ( FIG. 1 ) and dramatically outperforms these markers in their ability to discriminate risk (Table 1).
- suPAR has outperformed coronary artery calcium (CAC) score and hs-CRP in predicting all-cause death (Hayek et al., J Am Heart Assoc. 2018; 7(9)).
- the study was limited in the absence of longitudinal evaluation of CAC, and the select population (African Americans with diabetes mellitus). Also examined was the association between suPAR levels and carotid intima thickness, indices of vascular stiffness (augmentation index, pulse wave velocity), and endothelial function (brachial artery flow-mediated dilation) in 450 overall healthy participants (35% male, 22% African American, mean age of 50 years) of the Emory Predictive Health Project, a cohort of Emory University and Georgia Tech employees that volunteered for health screening.
- This subgroup had a ⁇ 10% prevalence of CV risk factors (hypertension, diabetes mellitus, and smoking), and suPAR levels were overall low (median suPAR of 2313 pg/ml, compared to 2950 pg/ml in the Emory Cardiovascular Biobank). While informative, the cross-sectional nature of these studies and their select population precludes determining whether high suPAR is associated with progression of subclinical disease.
- suPAR levels and CAC will first be examined in cross-sectional analyses as a primary outcome measure, and carotid intima-media thickness, augmentation index, pulse-wave velocity and flow-mediated dilation as secondary outcomes.
- SuPAR and CAC levels typically follow a non-normal distribution (right-skewed), and will be log-transformed for the purposes of parametric analyses.
- Kidney function will be estimated using creatinine-derived estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation (Levey et al., Ann Intern Med. 2009; 150(9):604-12).
- suPAR will be correlated with the aforementioned measures using Pearson's correlation.
- Multiple linear regressions will be used to model suPAR as a function of CAC adjusting for age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and diabetes mellitus to determine whether suPAR levels and the various subclinical markers of atherosclerosis are independently associated.
- power analyses a sample size of 5,784 will achieve 87% power to show that the expected Pearson's Correlation coefficient between suPAR and CAC of 0.18 is significantly higher than the null hypothesis correlation of 0.14, using a two-sided hypothesis test with a significance level of 0.05.
- Linear mixed modeling will be used by regressing CAC on suPAR, follow-up time (years since baseline CAC measure), suPAR ⁇ time, in addition to the aforementioned covariates including baseline CAC.
- the model will include a random subject-specific intercept and a random time effect to account for natural heterogeneity across subjects. Normalizing transformations (e.g., log) will be used if necessary to ensure accurate model fit.
- the interaction between suPAR and time in the model will be tested to show whether the progression pattern of CAC depends on suPAR. Three-way interaction terms will be incorporated into the model to determine whether gender, ethnicity, and decline in kidney function modify the association between suPAR and change in CAC.
- CAC missing data distributions will be checked, and if necessary, multiple imputation procedures and double robust analysis in data analysis will be considered. These associations will be examined in the subgroup of participants with CAC of 0 at baseline.
- power analyses a difference in the rate of change in CAC over time (i.e., the slope in the linear model assuming a constant rate) between low and high suPAR groups dichotomized by median is expected.
- a sample size of 5,784 will provide 86% power to detect a difference of 0.08 in slope or larger, assuming the standard deviation of the slopes in each group is 1, using a two-sided two-sample t test with equal variances at a significance level of 0.05.
- the actual power will likely be higher in the context of the linear mixed effects model due to efficiency gains from modeling repeated data and accounting for both within-group and between-group correlations.
- CHD coronary heart disease
- Cox proportional hazards regression will be used to study the effect of suPAR (groups or continuous value), after adjusting for age, gender, ethnicity, eGFR, smoking status, hypertension, LDL, HDL and diabetes mellitus.
- the integrated discrimination index (IDI), and net reclassification index (NRI) will be used to compare the ability of suPAR to discriminate risk of death and incident CHD as previously defined to that of CAC and hs-CRP.
- the baseline model will consist of the Atherosclerotic Cardiovascular Disease (ASCVD) risk score established in the latest guidelines of the American College of Cardiology and American Heart Association, and an important tool in clinical practice (Grundy et al., J Am Coll Cardiol. 2019; 73(24):e285-e350).
- power analyses based on preliminary data (Table 1, C-statistic of 0.663 for the risk factor model, and 0.721 with suPAR added) and the death rate of 10% at 8 years in MESA, there will 86% power to detect this hypothesized difference in the c-index, assuming years 90% of subjects have ⁇ 8 years follow-up or died in the study period, using a two-sided z-test at a significance level of 0.05.
- suPAR levels are expected to modestly correlate with CAC, but most importantly suPAR is expected to be a strong predictor of CAC progression and events, independently of clinical characteristics, ASCVD risk score, and kidney function.
- CAC represents a surrogate measure of atherosclerosis
- the absence of a relationship between suPAR and progression of CAC will decrease the likelihood of suPAR being involved in the pathogenesis of CVD, but does not exclude it.
- examining the association between suPAR and overall vascular calcifications will be considered; including evidence of atherosclerosis in other vascular beds, such as the carotids and aorta.
- This example describes experiments to identify genetic determinants of suPAR levels, and assess potential causality between suPAR and both CKD and CVD using Mendelian randomization (MR).
- MR Mendelian randomization
- MR analyses apply a rigorous statistical approach in the independent population to uncover causality between factor levels and the disease. Genome-wide association of studies of suPAR have not previously been reported.
- plasma suPAR was measured and a GWAS was performed in 3,244 young, healthy participants: 2,304 enrolled in the Trinity Student Study (TSS) and 940 in the Genes and Blood-Clotting (GABC) study.
- TSS Trinity Student Study
- GABC Genes and Blood-Clotting
- the Trinity Student Study is a cohort of 2,507 healthy and ethnically Irish individuals between 21 and 24 years old (59% female) attending University of Dublin, Trinity College who were recruited over the 2003-2004 academic year to study nutrition and metabolic phenotypes (Mills et al., The American Journal of Clinical Nutrition. 2011; 94(2):495-500).
- TSS The Trinity Student Study
- 2304 individual samples are available for study. Multiple studies have been performed on the plasma samples from TSS which were accessed with the permission of the TSS leadership.
- the original genotyping was performed on the Illumina Omni-1 quad with subsequent imputation to >7.2 million SNPs.
- the Genes and Blood-Clotting (GABC) study consists of a cohort of 1,189 young adults in 502 independent sibships recruited from the student population at the University of Michigan (NIH R37-HL039693, NIH R01-HL112642), which purpose was to study bleeding and coagulation phenotypes.
- the age range of GABC was 14-35 years with a median of age of 21.
- Sixty-three percent of GABC participants are female. This is a multiethnic cohort primarily composed of individuals of European origin (79%).
- the GABC Study was incorporated into the NIH Genes and Environment Initiative as part of the GENEVA (Gene Environment Association Studies) Consortium (Laurie et al., Nat Genet.
- DNA samples from both the GABC were genotyped using the Illumina HumanOmni1-Quad_v1-0_B array.
- genotyped SNPs from GABC and TSS were used to impute additional variants using the University of Michigan's public imputation server which now allows for the analysis of over 10 million SNPs in these cohorts.
- the UK Biobank project is a prospective cohort study with deep genetic and phenotypic data collected on approximately 500,000 individuals from across the United Kingdom, aged between 40 and 69 at recruitment (Bycroft et al., Nature. 2018; 562(7726):203-9). It is supported by the National Health Service (NHS). UK Biobank is open to bona fide researchers anywhere in the world, including those funded by academia and industry. Many groups have used this publicly available database to answer important questions about the genomic determinants of complex genetic traits. Genome-wide genotyping using UK BiLEVE Axiom Array by Affymetrix is available on all 488,377 participants. Data from the UK biobanks is accessed through a standard application process and is available to bona fide research groups. All findings are reported back to the UK Biobank at completion and shared with the scientific community.
- MESA genetic data contains Affymetrix 6.0 genotypes and Infinium HumanExome BeadChip data, produced as part of NHLBI's SNP Health Association Resource (SHARe) project. SNPs were imputed using IMPUTEv2.2.2 to the 1000 genomes cosmopolitan Phase 1 v3 as a reference (Bycroft et al., supra). More information on MESA is described above.
- suPAR antigen levels in these cohorts were not normally distributed. Therefore, the antigen level distribution was normalized by log transformation.
- the associations of smoking with raw suPAR level distribution were analyzed with Kolmogorov-Smirnov tests.
- the effects of BMI, weight, age, gender and population structure on the suPAR levels were determined by separate single-factor linear regression analysis.
- Narrow sense heritability (h2) of the suPAR level in the combined GABC and TSS dataset was first estimated by using the known sibship relationships, yielding an intraclass correlation-based upper bound estimate of 64.0%; consistent with the estimates derived from the genome-wide genotyping data for all individuals: 63.6% using MERLIN, and 64.0% using GCTA (Abecasis et al., Nat Genet. 2002; 30(1):97-101; Yang et al., Am J Hum Genet. 2011; 88(1):76-82).
- Meta-analysis was carried out using a fixed effect, sample-size-weighted approach implemented in METAL (Willer et al., Bioinformatics. 2010; 26(17):2190-1) using EMMAX association results for TSS and the European subset of GABC from a common set of 741,807 SNPs ( FIG. 3 ).
- the genomic control factors (Devlin et al., Theoretical Population Biology. 2001; 60(3):155-66) were corrected to 1.00 in meta-analysis by METAL.
- the results uncovered four independent loci associated with plasma suPAR levels. The strongest signal was in cis with the PLAUR locus encoding uPAR (suPAR).
- the top SNP rs4760(A), p 9.95 ⁇ 10 ⁇ 23 , has a minor allele frequency (MAF) of 16% in the gnomAD European subpopulations database and encodes the PLAUR missense variant L272P.
- Conditional analysis revealed a second independent locus at PLAUR with the top SNP rs2302524(T), p 1.17 ⁇ 10 ⁇ 11 .
- the second strongest signal was rs2633318(T), MAF 44%, p 5.84 ⁇ 10 ⁇ 15 near the PLAU locus, the gene encoding the suPAR ligand urokinase.
- rs2633318 has no current ClinVar associations.
- the former locus encoding a lymphocyte associated antigen and the latter a sialyltransferase enzyme that alters the sialic acid structures on N and 0 linked glycans common to many plasma proteins.
- a GWAS of plasma suPAR in the MESA study will be performed. SuPAR levels across cohorts are typically non-normally distributed, which will be normalized using log transformation. Significant associations with known covariates will be investigated, including the associations of smoking, the effects of BMI, weight, age, gender and population structure. Significant effects will be detected by separate single-factor linear regression analysis. Principal component (PC) scores will be regressed against the age and gender-corrected suPAR antigen levels, and the Pearson's correlation coefficients and p-values will be extracted. Genome-wide association tests will be conducted for all SNPs using an additive model and incorporating each PC score separately as a covariate to evaluate its impact on the genomic control factor (GC). After analyzing the Pearson's correlation coefficients, p-values and GC factors, the principal component(s) will be selected that are highly correlated with the suPAR levels and result in the lowest GC factors.
- PC Principal component
- a meta-analysis combining GWAS data from TSS/GABC and MESA cohorts will be performed. Specifically, a meta-analysis will be carried out using a fixed effect, sample-size-weighted approach implemented in METAL (Willer et al., supra) using EMMAX association results for TSS and the European subset of GABC from a common set of SNPs. The availability of imputed datasets of all three cohorts should facilitate the use of many shared SNPs. Genomic control factors (Devlin et al., supra) will be corrected to 1.000 in meta-analysis by METAL. Conditional analysis will then be performed on the top signals to determine the number of independent haplotypes at each major locus and to uncover possible interactions between cis and trans association signals.
- a Mendelian randomization study will then be performed to connect suPAR levels to risk for CKD and CVD.
- top signals from the meta-analysis of suPAR levels in sub-aims 2A and 2B will be candidate instrumental variables (IV) for suPAR.
- Phenotyping and genotyping data will be obtained from the UK Biobank (application in process).
- MR-Egger regressions and weighted median estimates (WME) will be performed to diagnose whether the instrumental variables for the main analysis estimates are valid.
- WME weighted median estimates
- the causal effect estimates produced by each of the individual variants will be examined using scatter plots, funnel plots, and forest plots and calculated heterogeneity statistics.
- IV will be removed from pleotropic loci which demonstrate known effects with multiple CVD/CKD related traits. Given ST3GAL4 loci SNP associations with other plasma antigens, these SNPs likely will be removed due to pleiotropy.
- This example describes experiments to establish whether suPAR is a modifiable risk factor for CVD.
- the CANTOS trial provided direct evidence that anti-inflammatory therapy can improve CV outcomes: patients with heart disease and elevated hs-CRP>2.0 mg/L randomized to canakinumab, a monoclonal antibody to interleukin 1 ⁇ had a lower rate of cardiovascular events and reduction in hs-CRP compared to the placebo group (Ridker et al., N Engl J Med. 2017; 377(12):1119-31). The improvement in outcomes was commensurate to the reduction in hsCRP (Lancet. 2018; 391(10118):319-28).
- suPAR is a stronger predictor of outcomes, and is associated with subclinical markers of CVD, warranting an investigation into its role as a potentially modifiable risk factor.
- SuPAR levels can be altered with lifestyle modifications (Eugen-Olsen et al., Eur J Clin Invest. 2016; 46(4):305-11; Haupt et al., Immun Ageing. 2019; 16:1). The most notable change in suPAR levels is reflected in smoking, with a decrease of 30% after 4 weeks of smoking cessation in a randomized trial (Eugen-Olsen et al., supra; Haupt et al., supra).
- statin therapy was associated with improved survival only in patients with suPAR ⁇ 3000 pg/mL (median suPAR level) ( FIGS. 5A and 5B ).
- the association was independent of traditional CV risk factors, including kidney function.
- suPAR levels modify the association between statins and outcomes
- the mean survival time in participants on statin therapy was 15.5 years, compared to 14.8 years for participants not on statins. Kaplan-Meier survival curves will be generated stratifying the cohort by statin therapy and suPAR level (lower or higher than the median).
- Cox proportional hazards regression will then be used to test the interaction between statins and suPAR (dichotomized or log-transformed continuous values) to assess whether the effect of statins on outcomes depends on the level of suPAR values. Additionally, this interaction will be tested after adjusting for potential confounders, such as age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and diabetes mellitus.
- potential confounders such as age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and diabetes mellitus.
- the survival rate assumed at 5 years is 0.75 in the statins vs 0.68 in the non-statins groups in subjects with a high suPAR value, the study lasting for 10 years with subject accrual in the first 5 years, and a dropout rate of 10%.
- the absolute and percentage change in suPAR levels will be compared between placebo and rosuvastatin arms, using the paired t-test if it is 1:1 matching; otherwise, using linear mixed effect model to consider the “clustered” data induced by the matching. Furthermore, simple linear regression will be used to correlate the magnitude of change in suPAR to that of hs-CRP and LDL (log transformation will be used if necessary) and Spearman correlation coefficients will be computed if the relationship is expected to be monotonic rather than linear. In power analyses, it is estimated that 200 subjects per arm will provide 80% power to detect an effect size of 0.2 (mean difference in suPAR change between two arms divided by the standard deviation of the difference), using a paired t-test at a significant level 0.05.
- statins Based on the preliminary data participants of MESA with high suPAR levels on statins will be expected have significantly better survival compared to those with similarly high levels but not on statins. Statins will have no impact on patients with low suPAR levels. A decrease in suPAR levels in the range of 10-20% with statin therapy compared to placebo also is expected.
- the MESA cohort will be used to translate findings from the Emory Cardiovascular Biobank and to determine whether suPAR modifies the association between statin and outcomes. If consistent with the preliminary data, these findings will be validated in the IMPROVE-IT trial, where a similar study has been done examining the roles of hs-CRP, hs-TnI, and BNP and a biomarker risk score in identifying patients who would benefit maximally from addition of ezetimibe. (107) suPAR also will be measured in MESA at a second time point (Exam 4), to assess whether the change in suPAR levels correlates with outcomes.
- Soluble urokinase plasminogen activator receptor is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. It was investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and experimental models were used to identify mechanisms by which suPAR acts and to assess it as a therapeutic target.
- the suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice.
- the suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation.
- Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells.
- This example describes characterization of the link between suPAR and HFpEF.
- SuPAR levels as a measure of overall burden of chronic inflammation, have been found to be predictive of incident HF in the general population, and cardiovascular mortality in patients with known HF independently of BNP (Koller et al., JACC Heart Fail. 2017; 5(4):268-77; Borne et al., Eur J Heart Fail. 2014; 16(4):377-83) Little is known of the underlying mechanisms, and whether suPAR levels correlate with measures of cardiac function and filling pressures.
- suPAR levels were previously measured in 4613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank, including 1157 with HF (mean age 64, 66% male, 26% black and 25% with EF ⁇ 45%) (Ko et al., supra). suPAR was found to be significantly higher in patients with HF compared to non-HF; and higher in HFpEF compared to HF with reduced ejection fraction (HFrEF). The association between suPAR and HF was independent of age, gender, body mass index, and clinical characteristics including hypertension, diabetes mellitus, renal function, and BNP levels.
- TOPCAT was a multicenter, international, randomized, double-blind, placebo-controlled trial designed to determine whether treatment with spironolactone compared with placebo would reduce mortality and morbidity in patients with HFpEF (Pitt et al., supra).
- Eligible patients included those ⁇ 50 years old with symptomatic HF and LVEF ⁇ 45%, controlled blood pressure, and either an HF hospitalization in the prior 12 months or elevated natriuretic peptide levels.
- patients were invited to contribute samples of serum, plasma, and urine to a biorepository. Patients that agreed to participate in this sub-study provided separate, written, informed consent to provide blood and urine samples at baseline and the 12-month study visit.
- suPAR was measured in blood samples of 404 patients with HFpEF enrolled in TOPCAT to confirm the above preliminary findings and investigate whether suPAR levels are associated with measures of elevated filling pressures and diastolic dysfunction grade. It was hypothesized that suPAR levels will correlate with indices of elevated filling pressures: diastolic dysfunction grade, E/e′ ratio, and BNP levels, independently of kidney function.
- suPAR levels in patients with HFpEF were compared to a matched non-HF cohort selected from the Emory Cardiovascular Biobank using 1:1 propensity score matching for age, gender, ethnicity, creatinine-derived estimated glomerular filtration rate (eGFR), smoking status, hypertension, diabetes mellitus, and BNP levels. Matching will create balanced covariate distributions between both groups. After log-transforming suPAR levels to a normal distribution an independent samples T-test will be used to compare suPAR values between both groups. For multivariable analyses logistic regression will be used with HFpEF as the dependent variable, and log-transformed suPAR in addition to the aforementioned variables and BNP forced in the model, to determine whether suPAR levels are independently associated with HFpEF.
- a sample size of 404 will achieve >95% power to detect a difference of 857 pg/mL when the significance level (alpha) of the test is 0.050 and the standard deviation is 2300.0 in both groups.
- the correlation between suPAR levels and measures of diastolic dysfunction will be examined; notably, diastolic dysfunction grade will be assessed using the modified Olmsted criteria as the primary outcome, and individual measures of diastolic dysfunction will be as secondary outcomes, including average E/e′ ratio, estimated pulmonary artery systolic pressures, and BNP levels (Nayor et al., J Am Heart Assoc. 2018; 7(11)). Spearman-Rank will be used to examine the univariable correlation between suPAR and diastolic dysfunction, and simple linear regression with log-transformed suPAR as the dependent variable and relevant clinical characteristics including eGFR and BNP as independent variables. In power analyses, a sample size of 404 achieves 83% power to detect a Spearman-Rank correlation of 0.15 (a conservative estimate) using a two-sided test with a significance level of 0.050.
- suPAR levels are expected to be significantly higher in patients with HFpEF, and to modestly correlate with measures of diastolic dysfunction and BNP levels in patients with HFpEF, suggesting suPAR levels are representative of the inflammatory process driving HFpEF.
- BNP Circ Heart Fail. 2011; 4(5):569-77.
- BNP is a dynamic biomarker whose increase results from myocardial stretch and high intracardiac filling pressures. Reduction in BNP levels are not associated with improved long term outcomes. It was examined whether suPAR, a marker of chronic inflammation with a link to HFpEF could be useful in identifying patients that would benefit from spironolactone.
- suPAR's association with incident HF independently of BNP in a general population cohort suggests levels may reflect the underlying pathogenic process leading to HF (Borne et al., Eur J Heart Fail. 2014; 16(4):377-83).
- the predictive ability of suPAR has been compared to hs-CRP, hs-TnI and BNP in 4,613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank (Nayor et al., J Am Heart Assoc. 2018; 7(11)), and found that suPAR is strongly predictive of outcomes including hospitalization for HF, and dramatically outperforms these markers in their ability to discriminate risk (Table 1).
- Kaplan-Meier survival curves will be generated stratifying the cohort by therapy (spironolactone and placebo) and suPAR level (lower or higher than the median).
- Cox proportional hazards regression will be used to test the interaction between therapy and suPAR (dichotomized by median or log-transformed continuous values) to assess whether the effect of spironolactone on outcomes depends on the level of suPAR values. Additionally, this interaction will be tested after adjusting for potential confounders, such as age, gender, and creatinine, smoking status, hypertension, LDL, HDL, and diabetes mellitus.
- a power analyses based on preliminary data from the Emory Cardiovascular Biobank used the following conservative assumptions: a dichotomized suPAR using the median as a cutoff, and a cumulative hazard rate at 3 years of 0.0093 in the low suPAR group ( ⁇ 3000 pg/mL) and 0.0976 in high suPAR group, a study duration of 3 years, with subject accrual in the first 1 years, and an estimated drop-out rate of 10%.
- 404 participants (191 in the placebo arm and 2013 in the spironolactone arm) there is >90% power to detect a difference in survival rate between high and low suPAR arms using a log-rank test at significant level of 0.05.
- the preliminary data shows a significant effect size for the association between suPAR and outcomes in HFpEF, which should be confirmed in TOPCAT participants.
- the overall number of TOPCAT participants with stored biorepository samples is smaller than the overall cohort (12%), and was dependent on patients agreeing to participate, lending a risk of selection bias. While that bias cannot be eliminated, it should be minimized by measuring suPAR in all available samples.
- the biomarker cohort had only minor differences in baseline characteristics compared to the residual TOPCAT population: participants were less likely to be black, had lower systolic blood pressure, and lower prevalence of hypertension and atrial fibrillation. Studies have been published using this smaller cohort (Anand et al., JACC Heart Fail. 2017; 5(4):241-52; and Myhre et al., supra) Nevertheless, the findings will represent compelling preliminary data to incorporate suPAR levels in the design of prospective studies of therapies for HFpEF.
- This example describes experiments to establish whether suPAR is a modifiable risk factor for HFpEF.
- HFpEF appears to be the end-result of a systemic pro-inflammatory state (see, e.g., Shah et al., supra, Paulus et al., J Am Coll Cardiol. 2013; 62(4):263-71, and Ter Maaten et al., Eur J Heart Fail. 2016; 18(6):588-98)
- clinical trials in HFpEF have mainly focused on the use of cardiovascular-specific therapies such as beta-blockers and angiotensin-receptor antagonists, and most recently neprilysin inhibition with little success.
- cardiovascular-specific therapies such as beta-blockers and angiotensin-receptor antagonists
- suPAR levels show minimal variation, an attribute that likely contributes to its strength as a biomarker of risk.
- suPAR is not an acute phase reactant and remains stable even in highly stressful conditions as myocardial infarction or cardiac surgery.
- suPAR levels can be altered with lifestyle modifications (Haupt et al., supra; and Eugen-Olsen et al., supra) with the most notable changes reflected in smoking cessation, with a decrease of 30% after 4 weeks post-cessation. Unhealthy dietary, exercise, and smoking habits were associated with a 44% increase in suPAR levels at 5 years in a general population study.
- suPAR levels can be modified by medical therapy is less clear.
- Simvastatin and Ezetimibe in Aortic stenosis trial patients who received statin and ezetimibe had a lower increase in suPAR levels at 4 years compared to placebo (4.1% vs. 9.2%) (Hodges et al., supra). Whether a change in suPAR levels is associated with outcomes has not been reported.
- suPAR levels were measured at 1-year post-enrollment to (a) address whether suPAR levels are modifiable using spironolactone, and (b) determine whether the change in suPAR is associated with the primary outcome of TOPCAT. It was hypothesized that suPAR levels at 1 year will be reduced in the spironolactone arm compared to placebo, and that a decrease in suPAR levels will be associated with better outcomes compared to unchanged or rising levels.
- suPAR levels are expected to be significantly decreased at 1-year in the spironolactone arm compared to the placebo arm, and patients with decreasing suPAR levels are expected to have longer event-free survival compared to those with increasing suPAR levels.
- suPAR The change in suPAR levels with spironolactone has not been previously explored, and the magnitude of change in suPAR varies depending on the intervention.
- suPAR at 5-years was overall 6% higher, which is a small change.
- a 30% decrease in suPAR levels was noted within 4 weeks.
- the overall small sample size may limit the ability to detect an association between small changes in suPAR and outcomes or perform subgroup analyses.
- suPAR will be measured at multiple time points in the MESA study to provide insight on whether the changes in levels are associated with outcomes.
- compositions, system, or method that do not materially affect the basic nature of the composition, system, or method.
- Many embodiments herein are described using open “comprising” language. Such embodiments encompass multiple closed “consisting of” and/or “consisting essentially of” embodiments, which may alternatively be claimed or described using such language.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 62/828,187, filed on Apr. 2, 2019, which is incorporated by reference herein.
- Provided herein are methods for guiding the treatment of cardiovascular diseases by measuring soluble urokinase plasminogen activator receptor (suPAR) protein levels in a subject in need thereof.
- The management of patients with cardiovascular diseases is often fraught with challenges in maximizing benefit and minimize risks of therapies, largely due to the significant heterogeneity amongst patients with similar disease processes. Biomarkers that reflect disease processes not accounted for by traditional clinical evaluation and that strongly predict outcomes including death, myocardial infarction, heart failure, and kidney disease would be valuable for guiding treatment decisions and personalizing therapy. Patients with cardiovascular disease represent a complex and heterogenous patient population, and there is a need for methods to determine which patients benefit preferentially from specific therapies; leading to overall more cost-effective and personalized treatment plans. The present disclosure provides such methods.
- The disclosure provides a method for treating cardiovascular disease in a subject, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from cardiovascular disease; (b) performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level; or (c) stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 3 ng/mL), whereby the cardiovascular disease in the subject is treated. In some embodiments, the cardiovascular disease is coronary artery disease (CAD), such as triple-vessel disease (TVD). In some embodiments, stenting is performed by percutaneous coronary intervention (PCI).
- The disclosure also provides a method of treating stable cardiovascular disease or preventing cardiovascular disease in a subject, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from stable cardiovascular disease or a subject at high risk for cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3.0 ng/mL); and (c) administering a statin, an immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented. In some embodiments, the subject suffers from stable cardiovascular disease. In some embodiments, the cardiovascular disease is coronary artery disease. In some embodiments, the subject is at high risk for cardiovascular disease and the method prevents cardiovascular disease. In some embodiments, the method comprises administering a statin to the subject. In some embodiments, the method comprises administering an immunomodulatory therapy to the subject, such as methotrexate, metformin, cananikumab, and a mineralocorticoid receptor antagonist. In some embodiments, the method comprises administering an anti-suPAR therapy to the subject, such as a monoclonal antibody that specifically binds to suPAR, or plasmapheresis using suPAR-specific cartridges.
- The disclosure also provides a method of preventing or treating cardiovascular disease using chelation therapy, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL) and (c) administering chelation therapy to the subject in the suPAR level is above the threshold level, thereby preventing cardiovascular disease in the subject. In some embodiments, the chelation therapy comprises administering ethylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid, or dimercaprol to the subject.
- The disclosure also provides a method of treating congestive heart failure in a subject with concomitant kidney dysfunction, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from congestive heart failure with concomitant kidney dysfunction; (b) performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than the threshold level; or (c) performing single organ heart transplantation if the level of suPAR in the sample is less than the threshold level, whereby the congestive heart failure in the subject is treated. In some embodiments, the mechanical circulatory support is a left ventricular assist device, a right ventricular assist device, or a total artificial heart.
- The disclosure also provides a method of treating kidney dysfunction in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from kidney dysfunction; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a treatment for kidney dysfunction to the subject, whereby the kidney dysfunction is treated in the subject.
- The disclosure also provides a method of treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from HFpEF; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a HFpEF treatment to the subject, such as mineralocorticoid antagonists, whereby HFpEF is treated in the subject.
- In some embodiments of the above-described methods, the sample is blood or urine, and the level of suPAR is determined or measured by immunoassay, immunoprecipitation, Western blot, flow cytometry, or protein microarray.
-
FIGS. 1A-1C are graphs showing the relationship between suPAR levels and the outcomes all-cause death (1A), cardiovascular death (1B), and hospitalization for heart failure (1C). Survival curves are stratified by suPAR quartiles. -
FIG. 2 is a graph showing suPAR levels 12 weeks after transfection of C57B6 mice at 20 weeks with PCSK9 (n=8) or saline (n=8). There was no difference in suPAR levels between groups, despite extensive atherosclerotic disease in PCSK9-transfected mice. -
FIG. 3 is a Manhattan plot of results from the GWAS of 3,244 participants. The top signal detected at the PLAUR locus is SNP rs4760 which encodes a nonsynonymous variant. Other significant signals are detected at the PLAU, LY75, and ST3GAL4 loci. -
FIG. 4 shows that suPAR levels are stable post-myocardial infarction. High-sensitivity C-reactive (hsCRP), suPAR, and troponin were measured serially in 296 consecutive patients presenting with an ST-elevation myocardial infarction. -
FIGS. 5A and 5B are graphs showing survival of patients stratified by statin therapy in patients with median suPAR levels <3000 pg/mL (5A) and patients with median suPAR levels >3000 pg/mL (5B). - Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments described herein, some preferred methods, compositions, devices, and materials are described herein. However, before the present materials and methods are described, it is to be understood that this invention is not limited to the particular compositions, methodologies, or protocols described herein, as these may vary in accordance with routine experimentation and optimization. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the embodiments described herein.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. However, in case of conflict, the present specification, including definitions, will control. Accordingly, in the context of the embodiments described herein, the following definitions apply.
- As used herein, the terms “administration” and “administering” refer to the act of giving a drug, prodrug, therapeutic, or other agent to a subject or in vivo, in vitro, or ex vivo cells, tissues, and organs. Exemplary routes of administration to the human body can be through space under the arachnoid membrane of the brain or spinal cord (intrathecal), the eyes (ophthalmic), mouth (oral), skin (topical or transdermal), nose (nasal), lungs (inhalant), oral mucosa (buccal), ear, rectal, vaginal, by injection (e.g., intravenously, subcutaneously, intratumorally, intraperitoneally, etc.) and the like.
- The terms “biomarker” and “biological marker” are used synonymously herein and refer to a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. In some embodiments, a biomarker may comprise a substance whose detection indicates a particular disease state (e.g., the presence of an antibody may indicate an infection). More specifically, a biomarker may indicate a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a particular treatment. The types of substances that may be measured as biomarkers range widely and include, but are not limited to, molecular biomarkers (e.g., nucleic acids, gene products, and proteins), physiologic biomarkers (e.g., blood pressure or blood flow), or anatomic biomarkers (e.g., the structure of a particular organ).
- As used herein, the terms “cardiovascular disease” (CVD) or “cardiovascular disorder” are terms used to classify numerous conditions affecting the heart, heart valves, and vasculature (e.g., veins and arteries) of the body and encompass diseases and conditions including, but not limited to arteriosclerosis, atherosclerosis, myocardial infarction, acute coronary syndrome, angina, congestive heart failure, aortic aneurysm, aortic dissection, iliac or femoral aneurysm, pulmonary embolism, primary hypertension, gestational hypertension, pre-eclampsia, atrial fibrillation, stroke, transient ischemic attack, systolic dysfunction, diastolic dysfunction, myocarditis, atrial tachycardia, ventricular fibrillation, endocarditis, arteriopathy, vasculitis, atherosclerotic plaque, vulnerable plaque, acute coronary syndrome, acute ischemic attack, sudden cardiac death, peripheral vascular disease, coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease.
- The term “cardiovascular event,” as used herein, refers to the manifestation of an adverse condition in a subject brought on by cardiovascular disease, such as sudden cardiac death or acute coronary syndromes including, but not limited to, myocardial infarction, gestational hypertension, pre-eclampsia, unstable angina, aneurysm, or stroke. The term “cardiovascular event” can be used interchangeably herein with the term “cardiovascular complication.” While a cardiovascular event can be an acute condition, it can also represent the worsening of a previously detected condition to a point where it represents a significant threat to the health of the subject, such as the enlargement of a previously known aneurysm or the increase of hypertension to life threatening levels.
- The term “coronary artery disease,” as used herein, refers to the narrowing or blockage of the coronary arteries due primarily to atherosclerosis (i.e., buildup of cholesterol and fatty deposits (“plaques”) on the inner walls of the arteries). The narrowing or blockage of the coronary arteries results in reduction of blood flow to the heart muscle. Coronary artery disease (also known as “ischemic heart disease (IHD)”) is the most common of the cardiovascular diseases, affecting 16.5 million Americans (Heart Disease and Stroke Statistics 2017 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. Jan. 25, 2017).
- As used herein, the term “diagnosis” encompasses determining the nature of disease in a subject, as well as determining the severity and probable outcome of disease or episode of disease and/or prospect of recovery (prognosis). “Diagnosis” can also encompass diagnosis in the context of rational therapy, in which the diagnosis guides therapy, including initial selection of therapy, modification of therapy (e.g., adjustment of dose and/or dosage regimen or lifestyle change recommendations), and the like.
- As used herein, the term “heart failure” refers to a condition in which the heart cannot pump blood efficiently to the rest of the body. Heart failure may be due to damage to the heart or narrowing of the arteries due to infarction, cardiomyopathy (primary or secondary), hypertension, coronary artery disease, valve disease, birth defects, or infection. Heart failure can further be described as chronic, congestive, acute, decompensated, systolic or diastolic. The New York Heart Association (NYHA) classification describes the severity of the disease based on functional capacity of the patient; NYHA class can progress and/or regress based on treatment or lack of response to treatment. In heart failure, “increased severity” of cardiovascular disease refers to the worsening of disease as indicated by increased NYHA classification, to, for example, Class III or Class IV, and “reduced severity” of cardiovascular disease refers to an improvement of the disease as indicated by reduced NYHA classification, from, for example, class III or IV to class II or I.
- The term “ejection fraction,” as used herein, refers to the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a subject's cardiac function. Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. Right ventricular ejection fraction (RVEF) is the measurement of how much blood is being pumped out of the right side of the heart to the lungs for oxygen. Typically, the term “ejection fraction” refers to left ventricular ejection fraction. Patients with an ejection fraction of 50 percent or higher are classified as having “heart failure with preserved ejection fraction” (HFpEF), whereas patients with an ejection fraction of less than 50 percent are classified as having “heart failure with reduced ejection fraction” (HFrEF) (see, e.g., Owan et al., N. Engl. J. Med., 355: 251-259 (2006); Hogg et al., J. Am. Coll. Cardiol., 43(3):317-2 (2004); Owan T, Prog. Cardiovasc. Dis., 47: 320-332 (2005); and Vasan R. S. et al., J. Am. Coll. Cardiol., 26: 1565-1574 (1995)).
- The terms “individual,” “host,” “subject,” and “patient” are used interchangeably herein and refer to any vertebrate, including, but not limited to, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (for example, a monkey, such as a cynomolgus monkey, chimpanzee, etc.) and a human). Preferably, the subject is a human. The terms “individual,” “host,” “subject,” and “patient” are used herein irrespective of whether the subject has or is currently undergoing any form of treatment.
- The terms “increased,” “increase,” and “elevated” may be used interchangeably herein and refer to an amount or a concentration in a sample that is higher or greater than a predetermined level or range, such as a typical or normal level found in a control group or control sample, or is higher or greater than another reference level or range (e.g., earlier or baseline sample). The terms “decreased,” “decrease,” “lowered,” and “reduced” may be used interchangeably herein and refer to an amount or a concentration in a test sample that is lower or less than a predetermined level or range, such as a typical or normal level found in a control group or control sample, or is lower or less than another reference level or range (e.g., earlier or baseline sample). The term “altered” refers to an amount or a concentration in a sample that is altered (increased or decreased) over a predetermined level or range, such as a typical or normal level found in a control group or control sample, or over another reference level or range (e.g., earlier or baseline sample).
- The terms “prevent,” “prevention,” “prophylactic,” and the like refer to completely or partially inhibiting onset of a disease or symptom thereof. A “prophylactically effective amount” of a particular compound, drug, or agent refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset).
- As used herein, the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect. Preferably, the effect is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptom attributable to the disease. A “therapeutically effective amount” of a particular compound, drug, or agent refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of a subject.
- The present disclosure is predicated, at least in part, on the discovery that the levels of soluble urokinase plasminogen activator receptor (suPAR) levels in blood are strongly predictive of several outcomes in cardiovascular disease patient populations, including death, myocardial infarction, heart failure and kidney disease, beyond traditionally measured markers of risk; and reflect a pathway of disease not accounted for by traditional testing. It has also been found that increased suPAR levels are predictive of kidney dysfunction and heart failure with preserved ejection fraction (HFpEF). In addition, measuring suPAR levels in hospitalized patients prior to discharge may help distinguish patients requiring earlier follow-up (e.g., patients with high suPAR) and/or initiation of telehealth monitoring strategies from patients who will benefit from delayed follow-up (e.g., patients with low suPAR). Thus, the use of suPAR as a biomarker in CVD patients will allow clinicians to better allocate resources and reduce hospitalization, thus improving the cost effectiveness of care.
- Soluble urokinase plasminogen activator receptor (suPAR) (NCBI Accession No. AAK31795) is the circulating form of a glycosyl-phosphatidylinositol-anchored three-domain membrane protein that is expressed on a variety of cells, including immunologically active cells, endothelial cells, podocytes, keratinocytes, fibroblasts, smooth muscle cells, megakaryocytes, and certain tumor cells (Thuno et al., Disease Markers, 27: 157-172 (2009); Wei et al., Nat Med, 14: 55-63 (2008); and Huai et al., Science, 311: 656-659 (2006)). Both the circulating and membrane-bound forms of suPAR are directly involved in the regulation of cell adhesion and migration through binding of integrins (Thuno et al., supra). The circulating form is produced by cleavage of membrane-bound urokinase-type plasminogen activator receptor and is readily detected in plasma, serum, urine, and other bodily fluids. Elevated suPAR levels have been associated with poor outcomes in various patient populations (see, e.g., Theilade et al., J Intern Med, 277: 362-371 (2015); Yoo et al., JA m Soc Nephrol, 26: 133-147 (2015); de Bock C E and Wang Y., Med Res Rev, 24: 13-39 (2004); Backes et al., Intensive Care Med, 38: 1418-1428 (2012); Borné et al., Eur J Heart Fail, 16: 377-383 (2014); Eugen-Olsen et al., J Intern Med, 268: 296-308 (2010); Fuhrman B., Atherosclerosis, 222: 8-14 (2012); Lyngbœk et al., Int J Cardiol, 167: 2904-2911 (2013); and Eapen et al., J Am Heart Assoc, 3: e001118-e001118 (2014)). Increased activation of the immune system leads to increased serum suPAR levels, which has been documented in several pathological conditions, including paroxysmal nocturnal hemoglobinuria, human immunodeficiency virus type 1 (HIV-1) infection, malaria, pneumococcal and Streptococcus pneumonia bacteraemia, sepsis, bacterial and viral CNS infection, active tuberculosis (TB) and also in various types of solid tumors (e.g., non-small cell lung cancer, breast, colorectal, prostate, and ovarian cancer) (Thuno et al., supra). suPAR also has been implicated in the pathogenesis of kidney disease, specifically focal segmental glomerulosclerosis and diabetic nephropathy, through interference with podocyte migration and apoptosis (Hayek et al., N Engl J Med, 373: 1916-1925 (2015)). Furthermore, high blood concentrations of suPAR independently predict high mortality in both patients and healthy individuals (Eugen-Olsen et al., Int J Tuberc Lung Dis, 6: 686-692 (2002)).
- The methods described herein involve measuring and determining the level of suPAR protein in a sample obtained from a subject. The terms “sample” and “biological sample” are used interchangeably herein and refer to bodily fluids such as blood-related samples (e.g., whole blood, serum, plasma, and other blood-derived samples), urine, cerebral spinal fluid, bronchoalveolar lavage, and the like. Another example of a sample is a tissue sample. A biological sample may be fresh or stored (e.g., blood or blood fraction stored in a blood bank). The biological sample may be a bodily fluid expressly obtained for the methods described herein or a bodily fluid obtained for another purpose which can be sub-sampled for the methods of this disclosure. In certain embodiments, the biological sample is whole blood. Whole blood may be obtained from the subject using standard clinical procedures. In other embodiments, the biological sample is plasma. Plasma may be obtained from whole blood samples by centrifugation of anti-coagulated blood, which provides a buffy coat of white cell components and a supernatant of the plasma. In certain embodiments, the biological sample may be serum. Serum may be obtained by centrifugation of whole blood samples that have been collected in tubes that are free of anti-coagulant. The blood is permitted to clot prior to centrifugation. The yellowish-reddish fluid that is obtained by centrifugation is the serum. In another embodiment, the sample may be urine. The sample may be pretreated as necessary by dilution in an appropriate buffer solution, heparinized, concentrated if desired, or fractionated by any number of methods, including but not limited to ultracentrifugation, fractionation by fast performance liquid chromatography (FPLC), or precipitation of apolipoprotein B containing-proteins with dextran sulfate or other methods. Any of a number of standard aqueous buffer solutions at physiological pH, such as phosphate, Tris, or the like, can be used. Methods well-known in the art for collecting, handling and processing urine, blood, serum and plasma, and other body fluids, may be used in the practice of the present disclosure.
- The level of suPAR protein may be measured, determined, and/or quantified using any suitable method for protein detection and/or quantification known in the art. Such methods include, but are not limited to, immunoassays (e.g., enzyme linked-immunosorbent assay (ELISA)), protein immunoprecipitation, immunoelectrophoresis, chemical analysis, SDS-PAGE and Western blot analysis, protein immunostaining, electrophoresis analysis, competitive binding assays, functional protein assays, protein microarray, or chromatography or spectrometry methods (e.g., high-performance liquid chromatography (HPLC), mass spectrometry, liquid chromatography-mass spectrometry (LC/MS), capillary electrophoresis (CE)-MS, or any separating front end coupled with MS detection and quantification) (see, e.g., Salvatore Sechi, Quantitative Proteomics by Mass Spectrometry (Methods in Molecular Biology) 2nd ed. 2016 Edition, Humana Press (New York, N.Y., 2009); Daniel Martins-de-Souza, Shotgun Proteomics: Methods and Protocols 2014 edition, Humana Press (New York, N.Y., 2014); Jörg Reinders and Albert Sickmann, Proteomics: Methods and Protocols (Methods in Molecular Biology) 2009 edition, Humana Press (New York, N.Y., 2009); and Jörg Reinders, Proteomics in Systems Biology: Methods and Protocols (Methods in Molecular Biology) 1st ed. 2016 edition, Humana Press (New York, N.Y., 2009)).
- In some embodiments, suPAR may be present in the sample at low levels that may not be efficiently detected using conventional methods. In such cases, the suPAR protein may be detected using ultrasensitive methodologies and devices specifically designed for detecting low abundant proteins in a sample. Examples of such methodologies and devices include, but are not limited to, microfluidic analytical systems (such as those described in, e.g., Martel, J. M. and Toner, M., Annu Rev Biomed Eng., 16: 371-96 (2014); Martel et al., Annu Rev Biomed Eng., 16: 371-96 (2014); Malhotra et al., Anal. Chem., 84, 6249-6255 (2012); and U.S. Patent Application Publication 2018/0161775 A1), ultra-sensitive ELISA assays (see, e.g., Schubert et al., Scientific Reports, 5: Article number: 11034 (2015)), and nanoparticle-based systems (see, e.g., Li et al., Biosensors and Bioelectronics, 68: 626-632 (2015)).
- Methods and devices for protein detection and quantification are further described in, e.g., Powers, A. D, and S. P. Palecek, Journal of Healthcare Engineering, 3(4): 503-534 (2012), and are available from a variety of commercial sources, any of which may be used in the methods described herein.
- In certain embodiments, the methods described herein involves comparing the levels of suPAR in a patient sample with a predetermined value or cutoff. The terms “predetermined cutoff,” “cutoff,” “predetermined value,” “reference level,” and “threshold level,” as used herein, refer to an assay cutoff value that is used to assess diagnostic, prognostic, or therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the predetermined cutoff/value already has been linked or associated with various clinical parameters (e.g., presence of disease, stage of disease, severity of disease, progression, non-progression, improvement of disease, etc.). The disclosure provides exemplary predetermined levels and reference levels. However, it is well-known that cutoff values may vary depending on the nature of the detection method or assay. Whereas the precise value of the predetermined cutoff/value may vary between assays, the correlations as described herein should be generally applicable.
- The predetermined value can take a variety of forms. For example, the predetermined value can be single cut-off value, such as a median or mean. The predetermined value can be established based upon comparative groups, such as where the risk of coronary artery disease in one defined group is double the risk in another defined group. In yet another alternative, the predetermined value can be a range, for example, where the tested population is divided equally (or unequally) into groups, such as-a low-risk group, a medium-risk group, and a high-risk group, or into quadrants, the lowest quadrant being individuals with the lowest risk and the highest quadrant being individuals with the highest risk.
- The predetermined value can depend upon the particular population selected. For example, an apparently healthy population will have a different normal range of biomarker expression levels than will a population comprised of patients with symptoms of cardiovascular disease or heart failure. In another embodiment, a population comprised of patients with congestive heart failure will have a different range of suPAR expression levels than will a population of patients with stable cardiovascular disease. Accordingly, the predetermined values selected may take into account the disease category in which an individual is grouped. Appropriate ranges and categories can be selected by those of ordinary skill in the art using routine methods. In some embodiments, an algorithm may be used to determine a predetermined value or threshold for decision making. Such an algorithm may consider a variety of factors, including, for example, (i) the age of the subject (e.g., higher threshold at higher age), (ii) renal function (e.g., lower threshold with better renal function because the kidneys are actively clearing suPAR), and (iii) gender (e.g., about 3 ng/mL suPAR (male) and about 4 ng/mL suPAR (female)).
- It will be appreciated that a “normal” or “baseline” level of suPAR protein in a sample obtained from a subject (e.g., a human subject) will vary depending on a variety of factors, such as the subject's gender, age, overall health, the sample type (e.g., whole blood, serum, etc.), the suPAR isoform measured, and the assay used for measuring suPAR levels. Generally, a normal level of suPAR in human blood (or blood fraction) is from about 2.5 ng/mL to about 5.0 ng/mL (e.g., about 2.5 ng/mL, about 3.0 ng/mL, about 3.5 ng/mL, about 4.0 ng/mL, about 4.5 ng/mL, or about 5.0 ng/mL). In some embodiments, a normal level of suPAR in human blood is less than 3.0 ng/mL (e.g., 2.9 ng/mL, 2.8 ng/mL, 2.7 ng/mL, 2.6 ng/mL, 2.5 ng/mL, 2.4 ng/mL, 2.3 ng/mL, 2.2 ng/mL, 2.1 ng/mL, 2.0 ng/mL, 1.9 ng/mL, 1.8 ng/mL, 1.7 ng/mL, 1.6 ng/mL, 1.5 ng/mL, 1.4 ng/mL, 1.3 ng/mL, 1.2 ng/mL, 1.1 ng/mL, 1.0 ng/mL, 0.9 ng/mL, 0.8 ng/mL, 0.7 ng/mL, 0.6 ng/mL, 0.5 ng/mL, 0.4 ng/mL, 0.3 ng/mL, 0.2 ng/mL, 0.1 ng/mL, 0.01 ng/mL, or less) (see, e.g., Rabna et al., PLoS One, 7(8): e43933 (2012); Lawn et al., BMC Infect Dis., 7: 41 (2007); and Schneider et al., BMC Infectious Diseases, 7: 134 (2007)). It will be appreciated that the normal level of suPAR in men is about 2.1 ng/mL and in women is about 2.5 ng/mL. A suPAR level that is higher than the normal range may be indicative of a pathological condition, such as kidney disease or cardiovascular disease. In other words, certain disease states may be indicated by blood suPAR protein levels greater than any suPAR level within the normal range of 2.5 ng/mL to about 5.0 ng/mL. For example, certain disease states may be indicated by blood suPAR protein levels greater than about 2.5 ng/mL (e.g., about 2.75 ng/mL, about 2.8 ng/mL, about 2.9 ng/mL, about 2.95 ng/mL, or greater), preferably greater than about 3.0 ng/mL (e.g., 3.5 ng/mL, 4.0 ng/mL, 4.5 ng/mL, or greater), and more preferably greater than about 5.0 ng/mL (e.g., 5.5 ng/mL, 6.0 ng/mL, 6.5 ng/mL, 7.0 ng/mL, 7.5 ng/mL, 8.0 ng/mL, 8.5 ng/mL, 9.0 ng/mL, 9.5 ng/mL, 10.0 ng/mL, 10.5 ng/mL, 15 ng/mL, 20 ng/mL, or greater). Furthermore, in patient populations which already exhibit high suPAR levels (e.g., cardiovascular patients), further elevation of suPAR levels within patient subpopulations may guide particular therapeutic interventions (e.g., bypass versus stenting), as discussed herein.
- The level of suPAR protein may be considered “elevated” if the level measured is above a predetermined threshold level. In one embodiment, such a threshold level can be set to the 90th-percentile or to the 95th-percentile of a healthy control population. Preferably, the threshold level is established at the 95th-percentile of a healthy control population. In some embodiments, a particular therapeutic decision or risk assessment for a subject suffering from, or at risk of suffering from, cardiovascular disease is indicated when the level of suPAR is at least 2-fold greater (e.g., 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50-fold, or greater) than a predetermined normal level of suPAR.
- In some embodiments, the disclosure provides a method for treating cardiovascular disease in a subject, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from cardiovascular disease; (b) performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL); or (c) stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 3 ng/ml), whereby the cardiovascular disease in the subject is treated. In some embodiments, the cardiovascular disease is coronary artery disease (as defined above). The coronary artery disease may be of any stage or severity. Coronary artery disease severity typically is determined by a number of factors, including but not limited to, left ventricular function, anatomic extent and severity of coronary atherosclerosis (e.g., the number of vessels with significant obstructive coronary disease), severity of ischemia, tempo and severity of angina and/or the presence of recent plaque rupture, and the patient's general health and noncoronary comorbid conditions. In some embodiments, the subject suffers from coronary artery disease with significant obstructive coronary disease in one, two, three, or four coronary blood vessels (e.g., single-, double-, triple-vessel, or quadruple-vessel disease). In one embodiment, the subject suffers from triple-vessel disease (TVD).
- In some embodiments, the method involves performing bypass surgery on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL). The terms “bypass,” “bypass surgery,” “coronary artery bypass surgery,” “coronary artery bypass graft (CABG) surgery,” and “heart bypass,” are used interchangeably herein and refer to a surgical procedure to restore normal blood flow to an obstructed coronary artery. CABG typically is performed to relieve angina unsatisfactorily controlled by maximum tolerated anti-ischemic medication, to prevent or relieve left ventricular dysfunction, and/or to reduce the risk of death. The surgery is usually performed with the heart stopped, necessitating the usage of cardiopulmonary bypass. CABG is often indicated when coronary arteries have a 50 to 99 percent obstruction. The obstruction being bypassed is typically due to arteriosclerosis, atherosclerosis, or both. The terms “single bypass,” “double bypass,” “triple bypass,” “quadruple bypass,” and “quintuple bypass” refer to the number of coronary arteries bypassed in the procedure. For example, a double bypass means two coronary arteries are bypassed (e.g., the left anterior descending (LAD) coronary artery and right coronary artery (RCA)); a triple bypass means three vessels are bypassed (e.g., LAD, RCA and left circumflex artery (LCX)); a quadruple bypass means four vessels are bypassed (e.g., LAD, RCA, LCX and first diagonal artery of the LAD), etc. Left main coronary artery obstruction requires two bypasses, one to the LAD and one to the LCX.
- In other embodiments, the method involves stenting one or more coronary arteries in the subject if the level of suPAR in the sample is less than a threshold level (e.g., about 3 ng/mL). The term “stenting,” as used herein, refers to the placement of a stent into a coronary artery. A “stent” is a tubular support placed temporarily inside a blood vessel, canal, or duct to aid healing or relieve an obstruction. Stenting is typically performed by percutaneous coronary intervention (PCI), which is a non-surgical procedure used to treat narrowing (stenosis) of coronary arteries. PCI, also known as “coronary angioplasty,” requires the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into coronary arteries (referred to as “cardiac catheterization”). PCI may be used to relieve symptoms of coronary artery disease or to reduce heart damage during or after a heart attack. The most prevalent stents used in the art are drug-eluting metal stents (DES), which have shown some benefits relative to bare metal stents with respect to early incidences of restenosis (Kang et al., J Am Coll Cardiol., 62(2): B251 (2014); Bosiers et al., Vasc Health Risk Manag., 4(43): 553 (2008)).
- In some embodiments, the disclosure provides a method of treating stable cardiovascular disease or preventing cardiovascular disease in a subject, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from stable cardiovascular disease or a subject at high risk for cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 2.5 ng/mL); and (c) administering a statin, an immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented. Descriptions of measuring and detecting suPAR, the sample, the subject, and components thereof described above also are applicable to those same aspects of the aforementioned method of treating stable cardiovascular disease or preventing cardiovascular disease in a subject.
- A cardiovascular disease may be considered “stable” if a patient is asymptomatic, or when symptoms, if present, are manageable with either medical or revascularization therapy. In some embodiments, the cardiovascular disease is coronary artery disease. “Stable coronary artery disease” is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischemia or hypoxia, which are usually inducible by exercise, emotion or other stress and are reproducible, but such episodes may also occur spontaneously. Such episodes of ischemia/hypoxia are commonly associated with transient chest discomfort (angina pectoris). SCAD also includes the stabilized, often asymptomatic, phases that follow an acute coronary syndrome (ACS) (2013 ESC Guidelines on the Management of Stable Coronary Artery Disease, The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology, European Heart Journal, 34, 2949-3003(2013)).
- In some embodiments, the subject is at high risk for developing cardiovascular disease, and the method prevents cardiovascular disease in the subject. A subject is considered “high risk” for developing cardiovascular disease, such as coronary artery disease, as a result of various conditions and behaviors including, but not limited to, high blood pressure, high cholesterol, diabetes, obesity, physical inactivity, unhealthy diet, smoking, and heavy alcohol consumption. A family history of cardiovascular disease, as well as age, race, and gender also are risk factors for heart disease. The term “high risk,” as used herein, is defined as greater than a 25% chance, preferably greater than or equal to a 30% chance, and more preferably greater than a 35% chance of a subject developing cardiovascular disease. The term “low risk,” as used herein, is defined as less than or equal to a 10% chance, preferably less than a 5% chance, and more preferably less than a 2% chance of a subject developing cardiovascular disease. The term “moderate risk,” as used herein, is defined as greater than a 10% and less than a 30% chance of a subject developing cardiovascular disease. The terms “risk assessment,” “risk classification,” “risk identification,” and “risk stratification,” as used herein, refers to the evaluation of factors including biomarkers, to predict the risk of occurrence of future events in a subject including disease onset or disease progression, so that treatment decisions regarding the subject may be made on a more informed basis.
- In some embodiments, the method involves determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 2.5 ng/mL; as described herein), and administering a statin, and immunomodulatory therapy, and/or an anti-suPAR therapy to the subject, whereby the cardiovascular disease in the subject is treated or prevented. Statins are a class of lipid-lowering drugs which inhibit HMG-CoA reductase and block the pathway for synthesizing cholesterol in the liver. Statins include, but are not limited to, atorvastatin (LIPITOR), fluvastatin (LESCOL), lovastatin (ALTOPREV), pitavastatin (LIVALO), pravastatin (PRAVACHOL), rosuvastatin (CRESTOR), and simvastatin (ZOCOR). The terms “immunomodulatory therapy” and “immunotherapy” are used interchangeably herein and refer to the treatment or prevention of a disease or condition by inducing, enhancing, suppressing or otherwise modifying an immune response. Immune dysregulation and inflammation contribute to the development of atherosclerotic plaques and their progression to acute coronary syndromes. In addition, increased circulating levels of biomarkers of systemic inflammation (e.g., high sensitivity C-reactive protein (hsCRP)) are correlated with a higher cardiovascular risk. Thus, targeting specific inflammatory pathways implicated in atherosclerotic plaque formation is the subject of ongoing research. Target-specific therapies directed at pro-inflammatory cytokines such as IL-1β, IL-6, TNFα, and CCL2 have demonstrated slowing in the progression of atherosclerosis in animal models and improved cardiovascular outcomes in human subjects (Khambhati et al., Atherosclerosis, 276: 1-9 (2018)). For example, the monoclonal antibody canakinumab directly targets and neutralizes IL-1β, and was recently shown to be associated with reduced risk of adverse cardiovascular events compared to placebo in a randomized, placebo-controlled trial (Ridker et al., Am. Heart J., 162: 597-605 (2011); and Ridker et al., N Engl. J. Med., 377: 1119-1131 (2017)). Several other therapies including colchicine, methotrexate, metformin, mineralocorticoid receptor antagonists (e.g., spironolactone or eplerenone), and leukotriene inhibitors demonstrate potential for lowering cardiovascular risk through immunomodulation. Any of the above-described immunotherapies, or other immunotherapeutic known in the art, may be used in connection with the methods described herein. In other embodiments, the method comprises administering an anti-suPAR therapy to the subject, such as a monoclonal antibody that specifically binds to suPAR (as described in, e.g., Rabanni et al., Neoplasia, 12(10): 778-788 (2010)), or plasmapheresis using suPAR-specific cartridges.
- In some embodiments, the disclosure provides a method of treating or preventing cardiovascular disease in a subject using chelation therapy, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject at risk of cardiovascular disease; (b) determining that the level of suPAR in the sample is greater than a threshold level (e.g., about 3 ng/mL); and (c) administering a chelation therapy to the subject, thereby treating or preventing cardiovascular disease in the subject. Descriptions of measuring and detecting suPAR, the sample, the subject, cardiovascular disease risk, and components thereof described above also are applicable to those same aspects of the aforementioned method of preventing cardiovascular disease in a subject.
- The term “chelation therapy,” as used herein, refers to a method for removing heavy metals, such as mercury or lead, from blood. Practitioners have used ethylene diamine tetraacetic acid (EDTA-based) chelation therapy to treat complications of atherosclerosis in diabetes for decades, but without robust evidence of its efficacy. In 2013, the Trial to Assess Chelation Therapy (TACT) study exhibited clinical benefit of an EDTA-based infusion regimen (40 infusions plus high-dose vitamins) in patients (>50 years of age) who had a prior myocardial infarction (MI) (Escolar et al., Circ Cardiovasc Qual Outcomes, 7: 15-24 (2014)). The chelation therapy may be performed using routine methods known in the art, and may comprise administering ethylenediaminetetraacetic acid (EDTA), dimercaptosuccinic acid, or dimercaprol to the subject.
- In some embodiments, the disclosure provides a method of treating congestive heart failure in a subject with concomitant kidney dysfunction, which method comprises: (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from congestive heart failure with concomitant kidney dysfunction; (b) performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 5 ng/mL); or (c) performing single organ heart transplantation on the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 5 ng/mL), whereby the congestive heart failure in the subject is treated. Descriptions of measuring and detecting suPAR, the sample, the subject, and components thereof described above also are applicable to those same aspects of the aforementioned method of treating congestive heart failure in a subject with concomitant kidney dysfunction.
- It is well known in the art that congestive heart failure (HF) (also commonly referred to as “heart failure”) is a leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). The accurate diagnosis and effective treatment of HF is challenging in patients with CKD due in part to a lack of validated imaging and biomarkers specifically in this population. The disclosed methods provide a solution to this problem in that suPAR protein levels in heart failure patients with concomitant kidney dysfunction indicate disease severity and can be used to guide treatment decisions. In some embodiments, for example, the method involves performing dual organ transplantation of the heart and kidney or mechanical circulatory support on the subject if the level of suPAR in the sample is greater than a threshold level (e.g., about 5 ng/mL) or performing single organ heart transplantation on the subject if the level of suPAR in the sample is less than the threshold level (e.g., about 5 ng/mL).
- The terms “heart transplant” and “cardiac transplant” are synonymous and refer to a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease when other medical or surgical treatments have failed. Heart transplants are most commonly performed by obtaining a functioning heart, with or without one or both lungs, from a recently deceased organ donor (brain death is the standard) and implanting the heart and one or both lungs into the patient. The recipient's own heart is either removed and replaced with the donor heart (i.e., an “orthotopic” transplant procedure) or, much less commonly, the recipient's diseased heart is left in place to support the donor heart (i.e., a “heterotopic” or “piggyback” transplant procedure). Approximately 3,500 heart transplants are performed every year in the world, more than half of which occur in the United States. The term “kidney transplant,” as used herein, refers to a surgical transplant procedure performed on patients with end-stage renal disease in which a healthy kidney from a live or deceased donor is placed into the diseased patient. More than 20,000 kidney transplants are performed annually in the U.S.
- The terms “mechanical circulatory support” or “mechanical circulatory support (MCS) device” are used interchangeably herein and refer to a device that either supplements or replaces the action of the failing heart or lungs. In certain embodiments, an MCS device is provided to heart failure patients who experience refractory cardiogenic shock, which is defined as cardiac and circulatory failure resulting in organ hypoperfusion. A variety of MCS devices are known in the art and can be used in connection with the disclosed methods (see, e.g., G. C. Stewart and M. M. Givertz, Circulation, 125: 1304-1315 (2012); Ryan et al., Korean Circ J., 49(3): 197-213 (2019); and Miller et al., Crit Care Med., 45(11): 1922-1929 (2017)). Suitable MCS devices include, for example, left or right ventricular assist devices (e.g., THORATEC® pVAD, BVS5000, AB5000, CENTRIMAG™, TANDEMHEART®, or IMPELLA®), an intra-aortic balloon pump (IABP), extra-corporeal membrane oxygenation (ECMO), and a total artificial heart (e.g., Abiomed TAH, CardioWest TAH).
- The disclosure also provides a method of treating kidney dysfunction in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from kidney dysfunction; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a treatment for kidney dysfunction to the subject, whereby the kidney dysfunction is treated in the subject. Descriptions of measuring and detecting suPAR, the sample, the subject, and components thereof described above also are applicable to those same aspects of the aforementioned method of treating kidney dysfunction in a subject. The method may be used to treat any condition causing kidney dysfunction, including, for example, acute kidney injury. Acute kidney injury occurs in 2 to 5% of hospitalized adults and has a major effect on morbidity and health care utilization (Bellomo et al., Lancet, 380: 756-66 (2012); Rewa O, Bagshaw S M, Nat Rev Nephrol, 10: 193-207 (2014); Lameire et al., Lancet, 382: 170-9 (2013); and Pakula A M, Skinner R A., J Intensive Care Med, 31: 319-24 (2016)). The largest burden of acute kidney injury occurs in critically ill patients and in persons with cardiovascular disease, who are at increased risk for both acute kidney injury and chronic kidney disease owing to their older age and multiple coexisting conditions, as well as their greater likelihood of undergoing procedures that may directly affect the kidneys, such coronary angiography or cardiac surgery (Pakula and Skinner, supra; McCullough et al., J Am Coll Cardiol; 68: 1465-73 (2016); and Wang Y, Bellomo R., Nat Rev Nephrol; 13: 697-711 (2017)).
- Inflammation and oxidative stress are central components of the pathogenesis of acute kidney injury, implicating multiple subtypes of immune cells (Tran et al., Nature 2016; 531: 528-32; and Rabb et al., J Am Soc Nephrol 2016; 27: 371-9). Evidence of a pathway linking the bone marrow to kidney injury has emerged, involving suPAR (Hayek et al., Nat Med, 23: 945-53 (2017); and Hayek et al., N. Engl. J. Med., 382: 416-26 (2020); doi: 10.1056/NEJMoa1911481). Levels of suPAR are strongly predictive of progressive decline in kidney function (Hahm et al., Nat Med., 23: 100-6 (2017); Hayek et al., Kidney Int Rep, 2: 425-32 (2017), Luo et al., Clin J Am Soc Nephrol., 13: 1013-21 (2018); Schaefer et al., JAMA Pediatr, 171(11): e172914 (2017); Schulz et al., Kidney Int Rep, 2: 239-47 (2017); and Hayek et al., J Am Soc Nephrol, 30: 1305-13 (2019)). Long-term exposure to elevated suPAR levels directly affects the kidneys by means of pathologic activation of αvβ3 integrin expressed in podocytes, resulting in proteinuria (Hayek et al., Nat Med, 23: 945-53 (2017); and Hayek et al., N. Engl., J. Med., 382: 416-26 (2020); doi: 10.1056/NEJMoa1911481).
- The kidney dysfunction treated by the disclosed method may also be chronic kidney disease (CKD). Chronic kidney disease affects close to 50 million people in the United States alone, with a growing disease burden over the past 15 years and 58% increase in attributable deaths since 2002 (Webster et al., Lancet, 389(10075): 1238-52 (2017); Bowe et al., JAMA Netw Open, 1(7): e184412 (2018); and Saran et al., Am J Kidney Dis.; 73(3S1): A7-A8 (2019)). People with CKD are disproportionately affected by cardiovascular disease (CVD), with two-thirds of patients having at least one form of CVD; atherosclerosis being the most common (Saran et al., supra; Gansevoort et al., Lancet, 382(9889): 339-52 (2013); and Benjamin et al., Circulation, 137(12): e67-e492 (2018)). Moreover, death from CVD is far more likely than progression to end-stage renal disease in this patient population (Saran et al., supra; Gansevoort et al., supra; and Benjamin et al., supra). Conversely, over 40% of patients with CVD have signs of kidney disease (Saran et al., supra).
- Recent work has elucidated mechanisms underlying the association between suPAR and CKD (see, e.g., Wei et al., Nat Med. 2008; 14(1):55-63; Hahm et al., Nat Med. 2017; 23(1):100-6.; Hayek et al., Nat Med. 2017; 23(8):945-53; Wei et al., J Clin Invest. 2019; 129(5):1946-59; and Wei et al., Nat Med. 2011; 17(8):952-60). SuPAR is released by Gr-1lo immature myeloid cells in response to pro-inflammatory stimuli to the bone marrow, and circulates to the kidneys where it binds to αvβ3 integrin expressed by podocytes (Wei et al., Nat Med. 2008; 14(1):55-63, Hahm et al., Nat Med. 2017; 23(1):100-6, and Wei et al., J Clin Invest. 2019; 129(5):1946-59). Pathologic integrin activation by suPAR induces podocyte cytoskeletal restructuring, autophagy, and effacement leading to proteinuria and chronic kidney dysfunction (Wei et al., Nat Med. 2008; 14(1):55-63, Hahm et al., Nat Med. 2017; 23(1):100-6, Wei et al., J Clin Invest. 2019; 129(5):1946-59, and Wei et al. Nat Med. 2011; 17(8):952-60). This mechanism acts in synergy with other risk factors for CKD, such as the presence of APOL1 mutations (Hayek et al., Nat Med. 2017; 23(8):945-53). Furthermore, interfering with the suPAR pathway, by bone marrow ablation, monoclonal antibody, (15) or small molecule inhibitors, can prevent and reverse kidney injury (Wei et al., Nat Med. 2008; 14(1):55-63, Hahm et al., Nat Med. 2017; 23(1):100-6; and Dal Monte et al., J Cell Mol Med. 2019; 23(2):1034-49).
- Any number or variety of treatment regimens for kidney dysfunction can be used. Examples of suitable treatment regimens or therapeutics include, for example, statins (described above) diuretics, angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, beta blockers, an anti-suPAR therapy (described above), a kidney transplant, dialysis, or a combination of any of the foregoing.
- The disclosure also provides a method of treating heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suffering from HFpEF; (b) determining that the level of suPAR in the sample is greater than a threshold level; and (c) administering a HFpEF treatment to the subject, whereby HFpEF is treated in the subject. Descriptions of measuring and detecting suPAR, the sample, the subject, and components thereof described above also are applicable to those same aspects of the aforementioned method of treating HFpEF in a subject.
- The burden of heart failure with preserved ejection (HFpEF) continues to grow, and is expected to outpace heart failure with reduced ejection fraction (HFrEF) in prevalence (Benjamin et al., Circulation. 2019; 139(10):e56-e5281, Savarese et al., Card Fail Rev. 2017; 3(1):7-11) Most importantly, HFpEF has posed a major clinical challenge for cardiovascular specialists, as the disease is associated with high morbidity and mortality, but does not respond to conventional therapies with proven efficacy in HFrEF. (Yusuf et al., Lancet. 2003; 362(9386):777-81; Cleland et al., Eur Heart J. 2006; 27(19):2338-45; Massie et al., N Engl J Med. 2008; 359(23):2456-67; Pitt et al., N Engl J Med. 2014; 370(15):1383-92; Solomon et al., N Engl J Med. 2019; Martin et al., Cochrane Database Syst Rev. 2018; 6:CD012721; and Redfield et al., N Engl J Med. 2015; 373(24):2314-24). Various studies have however suggested mineralocorticoid receptor antagonists (MRA) such as spironolactone as a promising therapy for HFpEF (Martin et al., supra; Edelmann et al., JAMA. 2013; 309(8):781-91, and Mottram et al., Circulation. 2004; 110(5):558-65). MRAs have been of particular interest in the management of HFpEF due to their effects on inflammation, interstitial fibrosis, myocardial stiffness, extracellular matrix expansion and vascular function, which are all key components in the pathogenesis of HFpEF (Jia et al., Biochim Biophys Acta Mol Basis Dis. 2017; 1863(8):2012-8; Briet et al., J Vasc Res. 2013; 50(2):89-99; Elinoff et al., Cardiovasc Res. 2018; 114(1):65-76; and Miura et al., J Pharmacol Sci. 2006; 101(3):256-9)
- Challenges in the management of HFpEF were highlighted by the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, assessing whether spironolactone would improve outcomes in HFpEF. The trial was unfortunately inconclusive (Pitt et al., supra). While spironolactone therapy did not decrease the incidence of the primary outcome in the overall study, a dramatic regional variation in the event rate was noted, with higher event rates in the North American cohort (29.5%) compared to Russia and the Republic of Georgia (8.9%) (Pfeffer et al., Circulation. 2015; 131(1):34-42). Post-hoc analyses showed that North American patients on spironolactone had a lower incidence of cardiovascular events compared to the placebo group (Pfeffer et al., supra). The difference was attributed to the inadequate selection of patients and lack of compliance with spironolactone. Overall, TOPCAT and other HFpEF trials have highlighted HFpEF as a heterogeneous disease with various comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency that drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction (Shah et al., Circulation. 2016; 134(1):73-90; and Paulus W J, Tschope C. J Am Coll Cardiol. 2013; 62(4):263-71). Blood-based biomarkers have been proposed as a method to accurately characterize HFpEF phenotypes and identify patients that would benefit from specific therapies (Shah et al., supra; Paulus and Tschope, supra; and Myhre et al., Circ Heart Fail.
- 2018; 11(11):e005312). As discussed herein, suPAR plays a known pathogenic role in kidney disease, which is a common co-morbid condition in patients with HFpEF. Experiments described in detail below show that outcomes in HFpEF are tightly linked to suPAR levels.
- Upon diagnosis of HFpEF, the subject may be administered any suitable HFpEF treatment. Treatment of HFpEF is largely governed by management of associated conditions and symptoms. Any number or variety of treatment regimens can be used, including any treatment that reduces the risk of developing HFpEF. Risk for developing HFpEF is reduced when systolic and diastolic blood pressure is less than about 140/90 mm Hg, or less than about 130/80 mm Hg if the subject has diabetes or renal disease. Examples of suitable treatment regimens or therapeutics include, for example, mineralocorticoid receptor antagonists and diuretics (to treat volume overload). If diuretics are chosen, it will be appreciated that volume depletion should be avoided. Angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and beta blockers can be used to treat hypertension but may not alter clinical outcomes in HFpEF. In patients with diabetes mellitus who are at risk for heart failure, diuretic-based antihypertensive therapy, ACE inhibitors, beta-blockers, glycemic control, and/or an anti-suPAR therapy (described above) can be employed to prevent heart failure. Clinicians also can encourage lifestyle changes in patients at risk of developing HFpEF, such as, for example, weight loss, smoking cessation, regular exercise, and a healthy diet.
- In some embodiments, the disclosure also provides a method to direct the post-hospital discharge care of patients admitted with, treated for, or at high risk of cardiovascular disease, which method comprises: (a) measuring the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained prior to discharge; (b) setting up a post-discharge follow-up in clinic within two weeks, telehealth monitoring or home care if the suPAR level in the sample is greater than a threshold level (e.g., about 3 ng/mL for men, and about 4 ng/mL for women) or (c) arranging for routine follow-up post-discharge for suPAR levels below the threshold. In some embodiments, telehealth monitoring is a cardiac event monitor, digital sensors, automated blood pressure monitoring, or an impedance monitor.
- In some embodiments, the disclosure provides methods of diagnosing a disease or condition that is associated with an increase in suPAR levels. In this regard, for example, the disclosure provides diagnosing a subject as suffering from such a disease or condition, which comprises (a) determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject suspected of suffering from the disease or condition, (b) comparing the amount of suPAR in the subject to a threshold level of suPAR if the level of suPAR in the sample is greater than a threshold level; and (c) detecting a level of suPAR in the subject that is greater than the threshold level; and (d) diagnosing the subject as suffering from the disease or condition. Descriptions of measuring and detecting suPAR, the sample, the subject, and components thereof described above also are applicable to those same aspects of the aforementioned method of diagnosing a disease or condition in a subject. The disease or condition may be any disease or condition described herein, including, but not limited to, cardiovascular disease (CVD), kidney dysfunction (e.g., chronic kidney disease (CKD) or acute kidney injury), congestive heart failure, and heart failure with preserved ejection fraction (HFpEF). Other diseases or conditions associated with increased levels of suPAR may be diagnosed in accordance with the methods described herein.
- The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
- This example demonstrates that suPAR is a strong biomarker of CVD risk and is associated with atherosclerosis.
- Levels of suPAR have been associated with incident CVD and poor outcomes in various patient groups, including critically ill patients, those with HIV, cancer, kidney disease, as well as the general population (see, e.g., Eapen et al., J Am Heart Assoc. 2014; 3(5):e001118, Edsfeldt et al., Stroke. 2012; 43(12):3305-12, 48-56; and Botha et al., Int J Cardiol. 2015; 184:631-6). The association is independent of its impact on the kidneys, as even patients with end-stage renal disease can be risk-stratified using suPAR (Drechsler et al., Clinical journal of the American Society of Nephrology: CJASN. 2017; 12(8):1265-73). Preliminary data from the Emory Cardiovascular Biobank (Ko et al., BMJ Open, 2017; 7: e018753) shows that suPAR is a strong predictor of risk, with patients in the 4th suPAR quartile (>3900 pg/ml) having a 5-year mortality close to 40% (
FIG. 1 ). SuPAR outperformed hs-CRP, high sensitivity troponin I (hsTnI) and B-type natriuretic peptide (BNP) in predicting outcomes of 4,613 patients undergoing coronary angiography for suspected CVD, as shown in Table 1. -
TABLE 1 SuPAR Compared to hs-TnI, hs-CRP and BNP in Predicting CV Death (all models adjusted for age, gender, race, BMI, smoking, hypertension, diabetes, eGFR, obstructive coronary artery disease, history) Cardiovascular Death Model C-statistic (95% CI) ΔC-statistic (95% CI) Model 1: Risk factors only 0.663 (0.621, 0.704) — Model 2: RF and suPAR 0.721 (0.679, 0.763) 0.058 (0.027,0.090) Model 3: RF and hs-TnI 0.676 (0.632, 0.721) 0.014 (−0.001, 0.029) Model 4: RF and hs-CRP 0.682 (0.633, 0.731) 0.016 (−0.006, 0.038) Model 5: RF and BNP 0.705 (0.679-0.730) 0.023 (0.006-0.039) - In other preliminary experimental work, suPAR levels were measured in a mouse model of atherosclerosis induced by injecting a gain-of-function adeno-associated viral (AAV) vector encoding the atherogenic D377Y mutation of the PCSK9 gene (Maxwell et al., Proc Natl Acad Sci USA. 2005; 102(6):2069-74). Expression of D377Y-PCSK9 led to dramatic increases in LDL by accelerating the degradation of the LDL receptor. This model was chosen to minimize off-target effects and the immunologic impact of the commonly used apoE or LDLr knockout mouse models (Oppi et al., Front Cardiovasc Med. 2019; 6:46). It was found that suPAR levels were not increased in mice with induced atherosclerosis compared to controls (
FIG. 2 ), suggesting that high suPAR levels are unlikely to be simply a consequence of atherosclerotic disease. - This example describes experiments to investigate if suPAR is a precursor of CVD.
- While suPAR levels are predictive of outcomes in various clinical settings, the mechanisms underlying this association are unclear (see, e.g., Eapen et al., supra, Edsfeldt et al., supra, and Arbel et al., Can J Cardiol. 2015; 31(10):1223-4.) Characterizing the relationship between suPAR and subclinical markers of CVD can offer valuable insights into implicated pathways. Several studies have found differential associations between suPAR and various indices of subclinical CVD. It has been reported in cross-sectional studies that coronary calcifications correlated with suPAR but not hs-CRP (Hayek et al., J Am Heart Assoc. 2018; 7(9); and Sorensen et al., Atherosclerosis. 2014; 237(1):60-6). Similarly, patients with high suPAR were more likely to have evidence of carotid plaques (Edsfeldt et al., supra; and Persson et al., Stroke. 2014; 45(1):18-23). Findings regarding suPAR's association with arterial stiffness as assessed by pulse-wave velocity were conflicting (Sehestedt et al., Atherosclerosis. 2011; 216(1):237-43; and Schutte et al., Thromb Res. 2012; 130(2):273-7). Overall, these studies suggest suPAR levels preferentially relate to atherosclerosis, however they are limited by the lack of longitudinal analyses, minimal ethnic diversity, and inadequate adjustment for potential confounders, notably kidney function.
- The Multi-Ethnic Study of Atherosclerosis (MESA) will be leveraged to provide clarity on the link between suPAR and subclinical markers of CVD, cross-sectionally, longitudinally, and in their association with outcomes. MESA is an NIH-funded prospective cohort initiated in July 2000 to investigate the prevalence, correlates, and progression of subclinical CVD in a population-based sample of 6,781 men (48%) and women (52%) aged 45-84 years, recruited from six field centers across the US. Approximately 38% of the cohort is White, 28% African American, 23% Hispanic, and 11% Asian. Individuals with known clinical CVD were excluded. Baseline measurements are listed in Table 2. Measurements of subclinical disease indicators and risk factors was repeated for the study of progression over 10 years. Participants were also followed for identification and characterization of CVD events, including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failure; therapeutic interventions for CVD; and mortality. Studies from MESA have provided key findings that have altered the practice of CV medicine such as the identification of CAC as a predictor of events and its clinical usefulness (Polonsky et al., JAMA. 2010; 303(16):1610-6; Detrano et al., N Engl J Med. 2008; 358(13):1336-45), and is the ideal cohort to characterize suPAR's role in the development of CVD in a multiethnic sample of the general population. suPAR will be measured in 5,784 samples from the MESA study.
-
TABLE 2 MESA Measurements at Exam 1Questionnaires Food Frequency (Diet) Medical Hx Medications Occupation/employment Personal Hx Physical Activity Psycho-Social Procedures/Assessments Ankle Brachial Index (ABI) Anthropometry Arterial Wave Form/Arterial Stiffness Blood Pressure Blood Sample collection CT Coronary (Chest) Electrocardiogram (ECG) Genotyping MRI Cardiac Urine collection US Carotid Distensibility US Carotid IMT US Plague US Endothelial Function (FMD) - Measuring suPAR:
- Plasma levels of suPAR will be measured using the Virogates ELISA kit (suPARnostic kit; Copenhagen, Denmark), which has a lower detection limit of 100 pg/mL and intra- and inter-assay variation of 2.75% and 9.17%, respectively, as determined by the assay manufacturer. Serum suPAR levels have shown stability extending up to 5 years in storage, and with repeated freeze-thaw. (82) All major publications on suPAR have used the suPARnostic assay (see, e.g., Diederichsen et al., Atherosclerosis. 2018; 271:245-51, Andersen et al., J Med Virol. 2008; 80(2):209-16, Botha et al., supra, and Sorensen et al., supra).
- Preliminary Results:
- The predictive ability of suPAR has been compared to hs-CRP, hs-TnI and BNP in 4,613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank (Ko et al., supra), and suPAR has been found to be strongly predictive of outcomes (
FIG. 1 ) and dramatically outperforms these markers in their ability to discriminate risk (Table 1). In a smaller cohort of 500 African Americans withtype 2 diabetes mellitus, suPAR has outperformed coronary artery calcium (CAC) score and hs-CRP in predicting all-cause death (Hayek et al., J Am Heart Assoc. 2018; 7(9)). SuPAR's correlation with CAC was modest (r=0.18, P<0.001), and remained significant after adjusting for relevant clinical characteristics including kidney function. The study was limited in the absence of longitudinal evaluation of CAC, and the select population (African Americans with diabetes mellitus). Also examined was the association between suPAR levels and carotid intima thickness, indices of vascular stiffness (augmentation index, pulse wave velocity), and endothelial function (brachial artery flow-mediated dilation) in 450 overall healthy participants (35% male, 22% African American, mean age of 50 years) of the Emory Predictive Health Project, a cohort of Emory University and Georgia Tech employees that volunteered for health screening. suPAR levels correlated with carotid intima media thickness (r=0.16, P<0.001), augmentation index (r=0.19, P<0.001), pulse wave velocity (r=0.10, P=0.046), but not flow-mediated dilation (r=−0.09, P=0.051). This subgroup had a <10% prevalence of CV risk factors (hypertension, diabetes mellitus, and smoking), and suPAR levels were overall low (median suPAR of 2313 pg/ml, compared to 2950 pg/ml in the Emory Cardiovascular Biobank). While informative, the cross-sectional nature of these studies and their select population precludes determining whether high suPAR is associated with progression of subclinical disease. - To quantify the relationship between suPAR levels and subclinical markers of CVD in MESA (n=5,784), the relationship between suPAR levels and CAC will first be examined in cross-sectional analyses as a primary outcome measure, and carotid intima-media thickness, augmentation index, pulse-wave velocity and flow-mediated dilation as secondary outcomes. SuPAR and CAC levels typically follow a non-normal distribution (right-skewed), and will be log-transformed for the purposes of parametric analyses. Kidney function will be estimated using creatinine-derived estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation (Levey et al., Ann Intern Med. 2009; 150(9):604-12). In univariate analysis suPAR will be correlated with the aforementioned measures using Pearson's correlation. Multiple linear regressions will be used to model suPAR as a function of CAC adjusting for age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and diabetes mellitus to determine whether suPAR levels and the various subclinical markers of atherosclerosis are independently associated. In power analyses, a sample size of 5,784 will achieve 87% power to show that the expected Pearson's Correlation coefficient between suPAR and CAC of 0.18 is significantly higher than the null hypothesis correlation of 0.14, using a two-sided hypothesis test with a significance level of 0.05.
- Next, longitudinal analyses will be performed to determine whether baseline suPAR is associated with progression of CAC. Table 3 shows the number of participants with CAC measures at each exam.
-
TABLE 3 Standard Valid N Mean Median Deviation Variance Range Exam 1 CAC 5784 152 1 424 179597 6316 Exam 2 CAC-22511 175 5 459 210777 5193 years Exam 3 CAC-4 2353 228 13 546 298154 5420 years Exam 4 CAC-6 987 282 26 623 388300 5814 years Exam 5 CAC-10 2691 302 48 615 378051 6389 years - Overall, 89% of participants had at least 2 CAC measures, and 50% had at least 3. Linear mixed modeling will be used by regressing CAC on suPAR, follow-up time (years since baseline CAC measure), suPAR×time, in addition to the aforementioned covariates including baseline CAC. The model will include a random subject-specific intercept and a random time effect to account for natural heterogeneity across subjects. Normalizing transformations (e.g., log) will be used if necessary to ensure accurate model fit. The interaction between suPAR and time in the model will be tested to show whether the progression pattern of CAC depends on suPAR. Three-way interaction terms will be incorporated into the model to determine whether gender, ethnicity, and decline in kidney function modify the association between suPAR and change in CAC. CAC missing data distributions will be checked, and if necessary, multiple imputation procedures and double robust analysis in data analysis will be considered. These associations will be examined in the subgroup of participants with CAC of 0 at baseline. In power analyses, a difference in the rate of change in CAC over time (i.e., the slope in the linear model assuming a constant rate) between low and high suPAR groups dichotomized by median is expected. A sample size of 5,784 will provide 86% power to detect a difference of 0.08 in slope or larger, assuming the standard deviation of the slopes in each group is 1, using a two-sided two-sample t test with equal variances at a significance level of 0.05. The actual power will likely be higher in the context of the linear mixed effects model due to efficiency gains from modeling repeated data and accounting for both within-group and between-group correlations.
- To determine whether suPAR's association with outcomes is dependent on progression of CAC and decline in kidney function, survival analyses will be performed to determine whether suPAR levels are associated with a-prior defined outcomes in MESA (Table 4).
-
TABLE 4 Events in MESA MI 324 Angina 347 CHF 358 PVD 118 Resuscitated Cardiac Arrest 38 PTCA 294 CABG 158 Other Revascularization 81 Stroke 304 TIA 98 Death CVD 164 Stroke 57 Other Athero 17 Other CVD 102 Non-CVD 173 Unknown 6 Non-Cardiovascular 955 (Ineligible Death) Composite Hard CHD 470 Endpoints All CHD 668 Hard CVD 732 All CVD 1007 Coronary Revascularization 412 - The primary outcome will be all-cause mortality (n=1248), and the secondary outcome will be incident coronary heart disease (CHD) (n=889), a composite endpoint of myocardial infarction, angina, resuscitated cardiac arrest and death from coronary disease. Average follow-up time was 13 years. In univariate analysis outcomes across suPAR quartiles will be compared using the log-rank test and Kaplan-Meier survival curves will be generated. Furthermore, Cox proportional hazards regression will be used to study the effect of suPAR (groups or continuous value), after adjusting for age, gender, ethnicity, eGFR, smoking status, hypertension, LDL, HDL and diabetes mellitus. The assumptions of proportional hazard and linear form of covariates (log or not) will be assessed by martingale residuals plots and the Kolmogorov-type supremum test. Various interactions will be tested to explore whether the association between suPAR and the survival outcome differs in subgroups defined by relevant variables, such as gender, age, ethnicity, diabetes mellitus, and baseline eGFR. Lastly, mediation analysis will be performed to quantify the direct contributions of suPAR to outcomes compared to CAC and decline in eGFR, using a single mediator model for CAC and eGFR separately as previously described (MacKinnon et al., J Public Health Dent. 2011; 71 Suppl 1:S37-46).
- In power analyses based on preliminary data, the following conservative assumptions were used: a dichotomized suPAR using the median as a cutoff, and a conservative estimate of survival (
FIG. 1 ) at 5 years of 0.95 in the low suPAR group and 0.75 in high suPAR group, a study duration of 10 years, with subject accrual in the first 5 years, and an estimated drop-out rate of 10%. With 5784 participants (2892 in each group), there is >95% power to detect a difference in survival rate between 0.95 in the low suPAR group and 0.75 in the low suPAR group (a conservative estimate), using a log-rank test at significant level of 0.05. Thus, this model is adequately powered to perform multivariable analyses, test interactions and subgroup analyses. - To compare suPAR's ability to discriminate risk compared to CAC and hs-CRP, Harrel's C-statistic, the integrated discrimination index (IDI), and net reclassification index (NRI) will be used to compare the ability of suPAR to discriminate risk of death and incident CHD as previously defined to that of CAC and hs-CRP. The baseline model will consist of the Atherosclerotic Cardiovascular Disease (ASCVD) risk score established in the latest guidelines of the American College of Cardiology and American Heart Association, and an important tool in clinical practice (Grundy et al., J Am Coll Cardiol. 2019; 73(24):e285-e350). The change in C-statistic, IDI, and NRI will be computed after addition of hs-CRP, CAC, and suPAR. These indices will be computed for the overall cohort, in addition to the low-risk group (n=2378, 41%) as defined by an ASCVD risk score of <7.5%. In power analyses, based on preliminary data (Table 1, C-statistic of 0.663 for the risk factor model, and 0.721 with suPAR added) and the death rate of 10% at 8 years in MESA, there will 86% power to detect this hypothesized difference in the c-index, assuming
years 90% of subjects have ≥8 years follow-up or died in the study period, using a two-sided z-test at a significance level of 0.05. - Expected Results:
- Based on preliminary findings suPAR levels are expected to modestly correlate with CAC, but most importantly suPAR is expected to be a strong predictor of CAC progression and events, independently of clinical characteristics, ASCVD risk score, and kidney function.
- While CAC represents a surrogate measure of atherosclerosis, not all plaque is calcified. Thus, the absence of a relationship between suPAR and progression of CAC will decrease the likelihood of suPAR being involved in the pathogenesis of CVD, but does not exclude it. To increase the sensitivity of these analyses, examining the association between suPAR and overall vascular calcifications will be considered; including evidence of atherosclerosis in other vascular beds, such as the carotids and aorta.
- This example describes experiments to identify genetic determinants of suPAR levels, and assess potential causality between suPAR and both CKD and CVD using Mendelian randomization (MR).
- Establishing causality between biomarkers and disease processes is fraught with challenges, given a multitude of factors can influence the levels of a given marker and confound-correlation causation inferences. Experimental models are costly and imperfect for numerous reasons, the most notable being the extrapolation of findings from animal and in vitro models to human physiology. Causality can however be strongly supported using human populations where associations between biomarkers and their genetic determinants—which have been randomly distributed in a population, and a specified disease outcome using MR (Sekula et al., J Am Soc Nephrol. 2016; 27(11):3253-65). An example of the power of MR in CVD is demonstrated by the studies that confirmed causality for LDL but not HDL in the pathogenesis of coronary artery disease (CAD). MR will test the hypothesis that suPAR is causally involved in CVD and CKD.
- If consistent with this hypothesis, adults with genetic predisposition to higher suPAR levels will also be more likely to have been diagnosed with CVD and or CKD. The key resources required for MR are independent populations that are genotyped across the genome and phenotyped for suPAR (GWAS study populations) or phenotyped for CVD and CKD (MR population). MR analyses apply a rigorous statistical approach in the independent population to uncover causality between factor levels and the disease. Genome-wide association of studies of suPAR have not previously been reported. As preliminary data, plasma suPAR was measured and a GWAS was performed in 3,244 young, healthy participants: 2,304 enrolled in the Trinity Student Study (TSS) and 940 in the Genes and Blood-Clotting (GABC) study. The findings will be replicated in a GWAS of MESA, a meta-analysis of all three cohorts will be performed to confirm the robustness of these findings, and then a MR analysis will be performed in 500,000 participants of the UK Biobank.
- The Trinity Student Study (TSS) is a cohort of 2,507 healthy and ethnically Irish individuals between 21 and 24 years old (59% female) attending University of Dublin, Trinity College who were recruited over the 2003-2004 academic year to study nutrition and metabolic phenotypes (Mills et al., The American Journal of Clinical Nutrition. 2011; 94(2):495-500). After genotype quality control and plasma assays, 2304 individual samples are available for study. Multiple studies have been performed on the plasma samples from TSS which were accessed with the permission of the TSS leadership. The original genotyping was performed on the Illumina Omni-1 quad with subsequent imputation to >7.2 million SNPs.
- The Genes and Blood-Clotting (GABC) study consists of a cohort of 1,189 young adults in 502 independent sibships recruited from the student population at the University of Michigan (NIH R37-HL039693, NIH R01-HL112642), which purpose was to study bleeding and coagulation phenotypes. The age range of GABC was 14-35 years with a median of age of 21. Sixty-three percent of GABC participants are female. This is a multiethnic cohort primarily composed of individuals of European origin (79%). The GABC Study was incorporated into the NIH Genes and Environment Initiative as part of the GENEVA (Gene Environment Association Studies) Consortium (Laurie et al., Nat Genet. 2012; 44(6):642-50; Machiela et al., Am J Hum Genet. 2015; 96(3):487-97, (90, 91)). DNA samples from both the GABC were genotyped using the Illumina HumanOmni1-Quad_v1-0_B array. The description of data cleaning/imputation steps and initial analyses are available at dbGaP (Desch et al., The Genes and Blood Clotting Study—dbGaP entry 2010 [Available from: ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000304.v1.p1]). Recently, genotyped SNPs from GABC and TSS were used to impute additional variants using the University of Michigan's public imputation server which now allows for the analysis of over 10 million SNPs in these cohorts.
- The UK Biobank project is a prospective cohort study with deep genetic and phenotypic data collected on approximately 500,000 individuals from across the United Kingdom, aged between 40 and 69 at recruitment (Bycroft et al., Nature. 2018; 562(7726):203-9). It is supported by the National Health Service (NHS). UK Biobank is open to bona fide researchers anywhere in the world, including those funded by academia and industry. Many groups have used this publicly available database to answer important questions about the genomic determinants of complex genetic traits. Genome-wide genotyping using UK BiLEVE Axiom Array by Affymetrix is available on all 488,377 participants. Data from the UK biobanks is accessed through a standard application process and is available to bona fide research groups. All findings are reported back to the UK Biobank at completion and shared with the scientific community.
- MESA genetic data contains Affymetrix 6.0 genotypes and Infinium HumanExome BeadChip data, produced as part of NHLBI's SNP Health Association Resource (SHARe) project. SNPs were imputed using IMPUTEv2.2.2 to the 1000 genomes
cosmopolitan Phase 1 v3 as a reference (Bycroft et al., supra). More information on MESA is described above. - Preliminary Results:
- In order to identify common genetic variants contributing to the variation in suPAR levels, and to estimate the heritability of suPAR, plasma suPAR levels were measured in GABC (n=1,152) (Desch et al., Proc Natl Acad Sci USA. 2013; 110(2):588-93, and TSS (n=2,304) (Stone et al., PLoS One. 2011; 6(7):e21851) using the Virogates ELISA kit (suPARnostic kit; Copenhagen, Denmark). These cohorts have a narrow age range (14-35 years) and are generally healthy, minimizing the confounding effects of renal disease, atherosclerosis and medical treatment on plasma suPAR levels. Consistent with previous studies, it was observed that suPAR antigen levels in these cohorts were not normally distributed. Therefore, the antigen level distribution was normalized by log transformation. The associations of smoking with raw suPAR level distribution were analyzed with Kolmogorov-Smirnov tests. The effects of BMI, weight, age, gender and population structure on the suPAR levels were determined by separate single-factor linear regression analysis. Narrow sense heritability (h2) of the suPAR level in the combined GABC and TSS dataset was first estimated by using the known sibship relationships, yielding an intraclass correlation-based upper bound estimate of 64.0%; consistent with the estimates derived from the genome-wide genotyping data for all individuals: 63.6% using MERLIN, and 64.0% using GCTA (Abecasis et al., Nat Genet. 2002; 30(1):97-101; Yang et al., Am J Hum Genet. 2011; 88(1):76-82). Single-SNP quantitative trait association analysis for the adjusted suPAR level were performed in TSS and the European subset of GABC using PLINK (Purcell et al., American Journal of Human Genetics; 2007; 81(3):559-75), and EMMAX (Efficient Mixed-Model Association eXpedited) (Kang et al., Nat Genet. 2010; 42(4):348-54). The genome-wide significance level is set at P=5×10−8 based on Bonferroni correction for 1 million independent tests.
- Meta-analysis was carried out using a fixed effect, sample-size-weighted approach implemented in METAL (Willer et al., Bioinformatics. 2010; 26(17):2190-1) using EMMAX association results for TSS and the European subset of GABC from a common set of 741,807 SNPs (
FIG. 3 ). The genomic control factors (Devlin et al., Theoretical Population Biology. 2001; 60(3):155-66) were corrected to 1.00 in meta-analysis by METAL. The results uncovered four independent loci associated with plasma suPAR levels. The strongest signal was in cis with the PLAUR locus encoding uPAR (suPAR). The top SNP rs4760(A), p=9.95×10−23, has a minor allele frequency (MAF) of 16% in the gnomAD European subpopulations database and encodes the PLAUR missense variant L272P. Conditional analysis revealed a second independent locus at PLAUR with the top SNP rs2302524(T), p=1.17×10−11. The second strongest signal was rs2633318(T), MAF 44%, p=5.84×10−15 near the PLAU locus, the gene encoding the suPAR ligand urokinase. rs2633318 has no current ClinVar associations. Two other trans loci had variants with genome-wide significance, rs10183731(G), p=1.80×10−8, MAF 42%, an intronic variant in the LY75 locus and rs11220465(A), p=2.54×10−8, MAF 17%, an intronic variant at the ST3GAL4 locus. The former locus encoding a lymphocyte associated antigen and the latter a sialyltransferase enzyme that alters the sialic acid structures on N and 0 linked glycans common to many plasma proteins. - In summary, these data demonstrate that suPAR levels are highly heritable in a healthy young population and using GWAS specific variants were identified in genes encoding uPAR, its ligand uPA, a lymphocyte-associated antigen and a sialyltransferase, which are associated with suPAR level variation. These initial findings support the aim of GWAS replication in a larger cohort (MESA) and subsequent MR studies in the UK Biobank.
- A GWAS of plasma suPAR in the MESA study will be performed. SuPAR levels across cohorts are typically non-normally distributed, which will be normalized using log transformation. Significant associations with known covariates will be investigated, including the associations of smoking, the effects of BMI, weight, age, gender and population structure. Significant effects will be detected by separate single-factor linear regression analysis. Principal component (PC) scores will be regressed against the age and gender-corrected suPAR antigen levels, and the Pearson's correlation coefficients and p-values will be extracted. Genome-wide association tests will be conducted for all SNPs using an additive model and incorporating each PC score separately as a covariate to evaluate its impact on the genomic control factor (GC). After analyzing the Pearson's correlation coefficients, p-values and GC factors, the principal component(s) will be selected that are highly correlated with the suPAR levels and result in the lowest GC factors.
- Single-SNP quantitative trait association analysis for the adjusted suPAR level will be performed in the European ancestry subset of MESA using PLINK (Purcell et al., supra), assuming an additive mode of allelic effect on unrelated samples. Compared to GABC and TSS, it is expected that the analysis of MESA samples will generate different distributions of suPAR levels and will have lower heritability estimates. Narrow sense heritability (h2) of suPAR levels in the sibling subset of the MESA dataset will be estimated by intraclass correlation. Likewise, estimates will also be derived from the genome-wide genotyping data for all individuals using MERLIN, and using GCTA software packages (Abecasis et al., supra; and Yang et al., supra).
- A meta-analysis combining GWAS data from TSS/GABC and MESA cohorts will be performed. Specifically, a meta-analysis will be carried out using a fixed effect, sample-size-weighted approach implemented in METAL (Willer et al., supra) using EMMAX association results for TSS and the European subset of GABC from a common set of SNPs. The availability of imputed datasets of all three cohorts should facilitate the use of many shared SNPs. Genomic control factors (Devlin et al., supra) will be corrected to 1.000 in meta-analysis by METAL. Conditional analysis will then be performed on the top signals to determine the number of independent haplotypes at each major locus and to uncover possible interactions between cis and trans association signals.
- A Mendelian randomization study will then be performed to connect suPAR levels to risk for CKD and CVD. To this end, top signals from the meta-analysis of suPAR levels in sub-aims 2A and 2B will be candidate instrumental variables (IV) for suPAR. Phenotyping and genotyping data will be obtained from the UK Biobank (application in process). MR-Egger regressions and weighted median estimates (WME) will be performed to diagnose whether the instrumental variables for the main analysis estimates are valid. To avoid bias due to pleiotropic effect of SNPs used in MR, the causal effect estimates produced by each of the individual variants will be examined using scatter plots, funnel plots, and forest plots and calculated heterogeneity statistics. This will allow selection of variants as IV as follows: first, IV will be removed from pleotropic loci which demonstrate known effects with multiple CVD/CKD related traits. Given ST3GAL4 loci SNP associations with other plasma antigens, these SNPs likely will be removed due to pleiotropy.
- Through GWAS meta-analysis, confirmation of the association of PLAUR, PLAU, LY75 and ST3GAL4 that were detected in the preliminary analysis in the GABC and TSS cohorts is expected. With the increased power of the additional MESA samples, additional signals should be detected (Table 5).
-
TABLE 5 Power calculations for GWAS of plasma suPAR levels. Power increases with heritability estimate and sample size. Alpha at 0.05 and individuals unrelated. Sample Size Heritability 940(GABC) 3340 (+TSS) 9340 (+MESA) 0.2 0.09 0.56 1 0.3 0.15 0.89 1 0.4 0.22 0.99 1 0.5 0.31 0.99 1 0.6 0.43 1 1 0.64 0.48 1 1 - In the MR study, confirmation of the causal association of suPAR with CKD and/or CVD is expected. This expectation is based on the strength of the preliminary data in both human and experimental models which has uncovered a pathogenic role for suPAR in kidney disease.
- Initial analyses in healthy young population estimates a high heritability of 64% and reveals strong associations at 4 gene loci. The addition of the MESA samples should increase power substantially to detect weaker associations. However, the power to detect associations in MESA may be weaker than in the GABC and TSS due to the presence of environmental modifiers of suPAR levels which include diabetes mellitus, smoking and unknown confounders. The loss of power is buffered by the relatively low amount of smoking (13%) and diabetes (12.6%) in MESA, the large number of participants (5,841), and previous work demonstrating the stability of suPAR levels despite environmental influences, such as acute inflammation, myocardial infarction (
FIG. 4 ) or circadian rhythm. The possible decreased power in MESA will be addressed through the stringent correction of significant covariates. Additionally, if necessary, analyses in additional genotyped cohorts will be performed, including investigations of suPAR levels in the Prevention of REnal and Vascular ENd-stage Disease cohort (PREVEND) (Pinto-Sietsma et al., Am Soc Nephrol. 2000; 11(10):1882-8 (Pinto-Sietsma et al., J Am Soc Nephrol. 2000; 11(10):1882-8). For the MR study, a positive result will strongly support the causal role for suPAR in CVD and CKD. Negative results, however, can be more difficult to interpret as they are reliant on the quality of the IV derived from GWAS resulting in a false negative study. This lack of power also can be addressed with additional cohort analyses in GWAS. - This example describes experiments to establish whether suPAR is a modifiable risk factor for CVD.
- The CANTOS trial provided direct evidence that anti-inflammatory therapy can improve CV outcomes: patients with heart disease and elevated hs-CRP>2.0 mg/L randomized to canakinumab, a monoclonal antibody to interleukin 1β had a lower rate of cardiovascular events and reduction in hs-CRP compared to the placebo group (Ridker et al., N Engl J Med. 2017; 377(12):1119-31). The improvement in outcomes was commensurate to the reduction in hsCRP (Lancet. 2018; 391(10118):319-28). While both hs-CRP and suPAR are conceptualized as markers of inflammation, suPAR is a stronger predictor of outcomes, and is associated with subclinical markers of CVD, warranting an investigation into its role as a potentially modifiable risk factor. SuPAR levels can be altered with lifestyle modifications (Eugen-Olsen et al., Eur J Clin Invest. 2016; 46(4):305-11; Haupt et al., Immun Ageing. 2019; 16:1). The most notable change in suPAR levels is reflected in smoking, with a decrease of 30% after 4 weeks of smoking cessation in a randomized trial (Eugen-Olsen et al., supra; Haupt et al., supra). A general population based observational study in Denmark showed unhealthy dietary, exercise and smoking habits was associated with a 44% increase in suPAR levels at 5 years (Haupt et al., supra)). Whether suPAR levels are modified by medical therapy is less clear. In the Simvastatin and Ezetimibe in Aortic stenosis trial, patients who received statin and ezetimibe had a much lower increase in suPAR levels at 4 years compared to placebo (4.1% vs. 9.2%) (Hodges et al., Atherosclerosis. 2018; 272:129-36). While suggestive of a possible impact of statins on suPAR levels, findings could have been confounded by the use of concomitant ezetimibe, and the fact that suPAR levels were measured 4 years apart.
- JUPITER is a randomized, double-blind trial of 17,603 participants (median age of 66, 39% women, 71% white) without prior cardiovascular disease or diabetes who were randomly allocated to rosuvastatin 20 mg or placebo and followed for up to 5 years for incident CVD (Ridker et al., N Engl J Med. 2008; 359: 2195-2207; Ridker, P. M. Circulation: Cardiovascular Quality and Outcomes. 2009; 2:279-285). Approval has been obtained to measure suPAR in 400 matched participants of JUPITER (n=200 in placebo, and n=200 in rosuvastatin arms), both at baseline and 1-year follow-up. Unfortunately, samples from patients with outcomes (cases) were depleted.
- In preliminary data from the Emory Cardiovascular Biobank where suPAR was measured in 4,613 patients undergoing coronary angiography (mean age 64, 64% male, 19% African American, 53% with known CVD), statin therapy was associated with improved survival only in patients with suPAR ≥3000 pg/mL (median suPAR level) (
FIGS. 5A and 5B ). The association was independent of traditional CV risk factors, including kidney function. These findings suggest that suPAR levels could be used to individualize therapy and to identify a subgroup that would maximally benefit from statins. - To determine whether suPAR levels modify the association between statins and outcomes, the interaction between suPAR and statins in their association with outcomes in MESA will examined. The primary outcome will be all-cause mortality (n=1248), and the secondary outcome will be incident CHD (n=889). A total of 1483 (26%) of MESA participants were on statin therapy, a proportion that remained relatively constant throughout the 5 years of the study. The mean survival time in participants on statin therapy was 15.5 years, compared to 14.8 years for participants not on statins. Kaplan-Meier survival curves will be generated stratifying the cohort by statin therapy and suPAR level (lower or higher than the median). Cox proportional hazards regression will then be used to test the interaction between statins and suPAR (dichotomized or log-transformed continuous values) to assess whether the effect of statins on outcomes depends on the level of suPAR values. Additionally, this interaction will be tested after adjusting for potential confounders, such as age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and diabetes mellitus. In power analyses based on the preliminary data (
FIGS. 5A and 5B ), the survival rate assumed at 5 years is 0.75 in the statins vs 0.68 in the non-statins groups in subjects with a high suPAR value, the study lasting for 10 years with subject accrual in the first 5 years, and a dropout rate of 10%. With 2892 subjects (half of subjects assuming median suPAR is used as a cut-off), assuming 20-26% are on statins, there will be 92-95% power to detect the hypothesized difference in the survival rates using a log-rank test at significant level of 0.05. - To determine whether statin therapy decreases suPAR levels, suPAR levels will be measured in 400 participants of the JUPITER trial (n=200 in each arm, placebo and rosuvastatin) at enrollment and 1-year follow-up. These participants will be selected from the overall cohort using propensity score matching after excluding those with abnormal creatinine values (creatinine >1.2 mg/dl). Specifically, subjects will be matched between the two arms based on age, gender, ethnicity, creatinine, smoking status, hypertension, LDL, HDL and hs-CRP levels. Matching will create balanced covariate distributions between the two arms. The absolute and percentage change in suPAR levels will be compared between placebo and rosuvastatin arms, using the paired t-test if it is 1:1 matching; otherwise, using linear mixed effect model to consider the “clustered” data induced by the matching. Furthermore, simple linear regression will be used to correlate the magnitude of change in suPAR to that of hs-CRP and LDL (log transformation will be used if necessary) and Spearman correlation coefficients will be computed if the relationship is expected to be monotonic rather than linear. In power analyses, it is estimated that 200 subjects per arm will provide 80% power to detect an effect size of 0.2 (mean difference in suPAR change between two arms divided by the standard deviation of the difference), using a paired t-test at a significant level 0.05.
- Expected Results:
- Based on the preliminary data participants of MESA with high suPAR levels on statins will be expected have significantly better survival compared to those with similarly high levels but not on statins. Statins will have no impact on patients with low suPAR levels. A decrease in suPAR levels in the range of 10-20% with statin therapy compared to placebo also is expected.
- The lack of samples from patients who met the endpoint in JUPITER may be a limitation. Thus, the MESA cohort will be used to translate findings from the Emory Cardiovascular Biobank and to determine whether suPAR modifies the association between statin and outcomes. If consistent with the preliminary data, these findings will be validated in the IMPROVE-IT trial, where a similar study has been done examining the roles of hs-CRP, hs-TnI, and BNP and a biomarker risk score in identifying patients who would benefit maximally from addition of ezetimibe. (107) suPAR also will be measured in MESA at a second time point (Exam 4), to assess whether the change in suPAR levels correlates with outcomes.
- This example demonstrates that a high level of suPAR predisposes patients to acute kidney injury in multiple clinical contexts.
- Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) is a signaling glycoprotein thought to be involved in the pathogenesis of kidney disease. It was investigated whether a high level of suPAR predisposed patients to acute kidney injury in multiple clinical contexts, and experimental models were used to identify mechanisms by which suPAR acts and to assess it as a therapeutic target.
- Using the methods described in Hayek et al., N Engl. J. Med., 382: 416-26 (2020); doi: 10.1056/NEJMoa1911481, plasma levels of suPAR were measured preprocedurally in patients who underwent coronary angiography and patients who underwent cardiac surgery and at the time of admission to the intensive care unit in critically ill patients. The risk of acute kidney injury was assessed at 7 days as the primary outcome and acute kidney injury or death at 90 days as a secondary outcome, according to quartile of suPAR level. In experimental studies, a monoclonal antibody to urokinase plasminogen activator receptor (uPAR) was used as a therapeutic strategy to attenuate acute kidney injury in transgenic mice receiving contrast material. Cellular bioenergetics and generation of reactive oxygen species were also assessed in human kidney proximal tubular (HK-2) cells that were exposed to recombinant suPAR.
- The suPAR level was assessed in 3827 patients who were undergoing coronary angiography, 250 who were undergoing cardiac surgery, and 692 who were critically ill. Acute kidney injury developed in 318 patients (8%) who had undergone coronary angiography. The highest suPAR quartile (vs. the lowest) had an adjusted odds ratio of 2.66 (95% confidence interval [CI], 1.77 to 3.99) for acute kidney injury and 2.29 (95% CI, 1.71 to 3.06) for acute kidney injury or death at 90 days. Findings were similar in the surgical and critically ill cohorts. The suPAR-overexpressing mice that were given contrast material had greater functional and histologic evidence of acute kidney injury than wild-type mice. The suPAR-treated HK-2 cells showed heightened energetic demand and mitochondrial superoxide generation. Pretreatment with a uPAR monoclonal antibody attenuated kidney injury in suPAR-overexpressing mice and normalized bioenergetic changes in HK-2 cells.
- The results of this example demonstrate that high suPAR levels are associated with acute kidney injury in various clinical and experimental contexts.
- This example describes characterization of the link between suPAR and HFpEF.
- Inflammation, a simple term for very complex processes, is thought to be the main driver of the pathophysiologic process leading to HFpEF. SuPAR levels, as a measure of overall burden of chronic inflammation, have been found to be predictive of incident HF in the general population, and cardiovascular mortality in patients with known HF independently of BNP (Koller et al., JACC Heart Fail. 2017; 5(4):268-77; Borne et al., Eur J Heart Fail. 2014; 16(4):377-83) Little is known of the underlying mechanisms, and whether suPAR levels correlate with measures of cardiac function and filling pressures.
- suPAR levels were previously measured in 4613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank, including 1157 with HF (mean age 64, 66% male, 26% black and 25% with EF<45%) (Ko et al., supra). suPAR was found to be significantly higher in patients with HF compared to non-HF; and higher in HFpEF compared to HF with reduced ejection fraction (HFrEF). The association between suPAR and HF was independent of age, gender, body mass index, and clinical characteristics including hypertension, diabetes mellitus, renal function, and BNP levels. SuPAR levels correlated modestly with HF symptoms as defined by NYHA class (r=0.15, P<0.001), and BNP levels (r=0.299, P<0.001). Interestingly, in multivariable analyses adjusting for both suPAR and BNP levels, only suPAR was significantly associated with HFpEF. Overall these findings suggest a link between suPAR and HF in general, and HFpEF in particular. These findings will be explored further detail in the TOPCAT trial.
- TOPCAT was a multicenter, international, randomized, double-blind, placebo-controlled trial designed to determine whether treatment with spironolactone compared with placebo would reduce mortality and morbidity in patients with HFpEF (Pitt et al., supra). Eligible patients included those ≥50 years old with symptomatic HF and LVEF ≥45%, controlled blood pressure, and either an HF hospitalization in the prior 12 months or elevated natriuretic peptide levels. At selected sites, patients were invited to contribute samples of serum, plasma, and urine to a biorepository. Patients that agreed to participate in this sub-study provided separate, written, informed consent to provide blood and urine samples at baseline and the 12-month study visit. Approval has been obtained to measure suPAR in all available baseline (n=404) and 12-month samples (n=328) of TOPCAT. The same primary study outcome will be used as the original TOPCAT; the composite of death from a cardiovascular cause, aborted cardiac arrest, or HF hospitalization (81 events). Mean duration of follow-up for the cohort was 2.6±1.5 years. <2% of data is missing in the available dataset.
- suPAR was measured in blood samples of 404 patients with HFpEF enrolled in TOPCAT to confirm the above preliminary findings and investigate whether suPAR levels are associated with measures of elevated filling pressures and diastolic dysfunction grade. It was hypothesized that suPAR levels will correlate with indices of elevated filling pressures: diastolic dysfunction grade, E/e′ ratio, and BNP levels, independently of kidney function.
- suPAR levels in patients with HFpEF were compared to a matched non-HF cohort selected from the Emory Cardiovascular Biobank using 1:1 propensity score matching for age, gender, ethnicity, creatinine-derived estimated glomerular filtration rate (eGFR), smoking status, hypertension, diabetes mellitus, and BNP levels. Matching will create balanced covariate distributions between both groups. After log-transforming suPAR levels to a normal distribution an independent samples T-test will be used to compare suPAR values between both groups. For multivariable analyses logistic regression will be used with HFpEF as the dependent variable, and log-transformed suPAR in addition to the aforementioned variables and BNP forced in the model, to determine whether suPAR levels are independently associated with HFpEF. In power analyses based on the preliminary data, a sample size of 404 will achieve >95% power to detect a difference of 857 pg/mL when the significance level (alpha) of the test is 0.050 and the standard deviation is 2300.0 in both groups.
- The correlation between suPAR levels and measures of diastolic dysfunction will be examined; notably, diastolic dysfunction grade will be assessed using the modified Olmsted criteria as the primary outcome, and individual measures of diastolic dysfunction will be as secondary outcomes, including average E/e′ ratio, estimated pulmonary artery systolic pressures, and BNP levels (Nayor et al., J Am Heart Assoc. 2018; 7(11)). Spearman-Rank will be used to examine the univariable correlation between suPAR and diastolic dysfunction, and simple linear regression with log-transformed suPAR as the dependent variable and relevant clinical characteristics including eGFR and BNP as independent variables. In power analyses, a sample size of 404 achieves 83% power to detect a Spearman-Rank correlation of 0.15 (a conservative estimate) using a two-sided test with a significance level of 0.050.
- Based on the preliminary findings, suPAR levels are expected to be significantly higher in patients with HFpEF, and to modestly correlate with measures of diastolic dysfunction and BNP levels in patients with HFpEF, suggesting suPAR levels are representative of the inflammatory process driving HFpEF.
- The diagnosis of HFpEF is reliant on the incorporation of multiple dynamic variables such as diastolic dysfunction and BNP levels; both of which can be modified with therapy. Thus, the absence of a correlation between suPAR and these indices cannot rule out the existence of an association between HFpEF and suPAR. The hypothesis that suPAR levels reflect a pathogenic process leading to HF can be explored in a longitudinal approach. Approval has been obtained to measure suPAR in the Multi-Ethnic Study of Atherosclerosis (MESA), in which participants from the general population have been extensively characterized and underwent follow-up for events including incident HFpEF. MESA will be leveraged to determine whether participants with high suPAR levels are at high risk of incident HFpEF.
- Despite extensive investigation, effective therapies in improving outcomes in patients with HFpEF have yet to be identified (Yusef et al., supra; Cleland et al., supra; Massie et al., supra; Pitt et al, supra; and Solomon et al., supra). The lack of benefit is attributed at least partially to the phenotypic diversity of HFpEF (Shah et al., supra). Posthoc analyses of HFpEF clinical trials have suggested biomarkers such as BNP can identify subgroups of patients with HFpEF that may benefit from certain therapies such as spironolactone or irbesartan (Pfeffer et al., supra; Anand et al., JACC Heart Fail. 2017; 5(4):241-52., and Anand et al., Circ Heart Fail. 2011; 4(5):569-77). BNP, however, is a dynamic biomarker whose increase results from myocardial stretch and high intracardiac filling pressures. Reduction in BNP levels are not associated with improved long term outcomes. It was examined whether suPAR, a marker of chronic inflammation with a link to HFpEF could be useful in identifying patients that would benefit from spironolactone.
- Preliminary Results:
- suPAR's association with incident HF independently of BNP in a general population cohort suggests levels may reflect the underlying pathogenic process leading to HF (Borne et al., Eur J Heart Fail. 2014; 16(4):377-83). The predictive ability of suPAR has been compared to hs-CRP, hs-TnI and BNP in 4,613 patients undergoing coronary angiography for suspected CVD and enrolled in the Emory Cardiovascular Biobank (Nayor et al., J Am Heart Assoc. 2018; 7(11)), and found that suPAR is strongly predictive of outcomes including hospitalization for HF, and dramatically outperforms these markers in their ability to discriminate risk (Table 1). Most importantly, it found that the association between HFpEF and outcomes, specifically cardiovascular death and all-cause death, are dependent on suPAR levels: patients with HFpEF and suPAR levels <3000 pg/ml (median) had similar outcomes compared to patients without HF, while those with HFpEF and suPAR ≥3000 pg/ml had significantly worse outcomes compared to non-HFpEF. This association was independent of gender or ethnicity. These preliminary findings support the use of suPAR in identifying high-risk HFpEF patients, but need to be replicated in a non-select group of HFpEF patients.
- To confirm suPAR's association with outcomes in HFpEF, survival analyses were performed to determine whether suPAR levels are associated with the primary outcome in TOPCAT. In univariate analysis outcomes will be compared across suPAR tertiles using the log-rank test and produce Kaplan-Meier survival curves. Cox proportional hazards regression will then be used to study the effect of suPAR (groups or continuous value) on a step-wise fashion: the initial model will include suPAR alone, followed by forced entry of age, gender, ethnicity, eGFR, smoking status, hypertension, diabetes mellitus, and lastly, addition of diastolic dysfunction grade and BNP levels. The assumptions of proportional hazard and linear form of covariates (log-transformed or not) will be assessed by martingale residuals plots and the Kolmogorov-type supremum test.
- To assess whether suPAR levels modify the association between treatment and outcomes, Kaplan-Meier survival curves will be generated stratifying the cohort by therapy (spironolactone and placebo) and suPAR level (lower or higher than the median). Cox proportional hazards regression will be used to test the interaction between therapy and suPAR (dichotomized by median or log-transformed continuous values) to assess whether the effect of spironolactone on outcomes depends on the level of suPAR values. Additionally, this interaction will be tested after adjusting for potential confounders, such as age, gender, and creatinine, smoking status, hypertension, LDL, HDL, and diabetes mellitus.
- A power analyses based on preliminary data from the Emory Cardiovascular Biobank used the following conservative assumptions: a dichotomized suPAR using the median as a cutoff, and a cumulative hazard rate at 3 years of 0.0093 in the low suPAR group (<3000 pg/mL) and 0.0976 in high suPAR group, a study duration of 3 years, with subject accrual in the first 1 years, and an estimated drop-out rate of 10%. With 404 participants (191 in the placebo arm and 2013 in the spironolactone arm), there is >90% power to detect a difference in survival rate between high and low suPAR arms using a log-rank test at significant level of 0.05. Thus, there is adequate power to perform multivariable analyses, test interactions, and subgroup analyses.
- Expected Results:
- Based on this preliminary data, confirmation of a strong association between suPAR and outcomes in HFpEF is expected. An interaction between suPAR levels and treatment in their association with outcomes will represent a novel finding that has important implications for both clinical trial design and treatment of HFpEF patients, but will require prospective validation.
- The preliminary data shows a significant effect size for the association between suPAR and outcomes in HFpEF, which should be confirmed in TOPCAT participants. However, the overall number of TOPCAT participants with stored biorepository samples is smaller than the overall cohort (12%), and was dependent on patients agreeing to participate, lending a risk of selection bias. While that bias cannot be eliminated, it should be minimized by measuring suPAR in all available samples. The biomarker cohort had only minor differences in baseline characteristics compared to the residual TOPCAT population: participants were less likely to be black, had lower systolic blood pressure, and lower prevalence of hypertension and atrial fibrillation. Studies have been published using this smaller cohort (Anand et al., JACC Heart Fail. 2017; 5(4):241-52; and Myhre et al., supra) Nevertheless, the findings will represent compelling preliminary data to incorporate suPAR levels in the design of prospective studies of therapies for HFpEF.
- This example describes experiments to establish whether suPAR is a modifiable risk factor for HFpEF.
- Although HFpEF appears to be the end-result of a systemic pro-inflammatory state (see, e.g., Shah et al., supra, Paulus et al., J Am Coll Cardiol. 2013; 62(4):263-71, and Ter Maaten et al., Eur J Heart Fail. 2016; 18(6):588-98), clinical trials in HFpEF have mainly focused on the use of cardiovascular-specific therapies such as beta-blockers and angiotensin-receptor antagonists, and most recently neprilysin inhibition with little success. There have been no attempts at targeting the inflammatory process in HFpEF, beyond addressing underlying co-morbidities. The data on spironolactone as a therapy is promising, and its benefits are thought to at least partially relate to its immunomodulatory activity. Thus, the ability of spironolactone to reduce inflammation was assessed by measuring suPAR levels, and it was examined whether the reduction translates to better outcomes.
- Preliminary Results:
- Generally, suPAR levels show minimal variation, an attribute that likely contributes to its strength as a biomarker of risk. Compared to other inflammatory markers such as hs-CRP or IL-6, suPAR is not an acute phase reactant and remains stable even in highly stressful conditions as myocardial infarction or cardiac surgery. However, suPAR levels can be altered with lifestyle modifications (Haupt et al., supra; and Eugen-Olsen et al., supra) with the most notable changes reflected in smoking cessation, with a decrease of 30% after 4 weeks post-cessation. Unhealthy dietary, exercise, and smoking habits were associated with a 44% increase in suPAR levels at 5 years in a general population study. Whether suPAR levels can be modified by medical therapy is less clear. In the Simvastatin and Ezetimibe in Aortic stenosis trial, patients who received statin and ezetimibe had a lower increase in suPAR levels at 4 years compared to placebo (4.1% vs. 9.2%) (Hodges et al., supra). Whether a change in suPAR levels is associated with outcomes has not been reported.
- suPAR levels were measured at 1-year post-enrollment to (a) address whether suPAR levels are modifiable using spironolactone, and (b) determine whether the change in suPAR is associated with the primary outcome of TOPCAT. It was hypothesized that suPAR levels at 1 year will be reduced in the spironolactone arm compared to placebo, and that a decrease in suPAR levels will be associated with better outcomes compared to unchanged or rising levels.
- To assess whether spironolactone decreases suPAR levels, the absolute and percentage change in suPAR levels were compared from enrollment to 1-year between placebo and spironolactone arms using a paired t-test in univariable analysis, and a linear mixed effect model will be used to adjust for differences in clinical characteristics between arms. In power analyses, 200 subjects per arm are estimated to provide 80% power to detect an effect size of 0.2 (mean difference in suPAR change between two arms divided by the standard deviation of the difference), using a paired t-test at a significant level 0.05.
- To determine whether the change in suPAR levels at 1-year are associated with outcomes, the absolute and percentage change in suPAR levels will be computed in survival analyses Kaplan-Meier survival curves will be produced comparing survival between patients with increasing vs. decreasing or unchanged suPAR levels using the Log-rank test. Cox proportional hazards regression will be used to adjust for relevant clinical characteristics including age, gender, hypertension, diabetes mellitus, kidney function, and randomization strategy, in addition to examining the interaction between randomization strategy and change in suPAR levels.
- Expected Results:
- suPAR levels are expected to be significantly decreased at 1-year in the spironolactone arm compared to the placebo arm, and patients with decreasing suPAR levels are expected to have longer event-free survival compared to those with increasing suPAR levels.
- The change in suPAR levels with spironolactone has not been previously explored, and the magnitude of change in suPAR varies depending on the intervention. In a population based non-interventional study, suPAR at 5-years was overall 6% higher, which is a small change. However, in a randomized trial of smoking cessation, a 30% decrease in suPAR levels was noted within 4 weeks. The overall small sample size may limit the ability to detect an association between small changes in suPAR and outcomes or perform subgroup analyses. suPAR will be measured at multiple time points in the MESA study to provide insight on whether the changes in levels are associated with outcomes.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Conversely, the term “consisting of” and linguistic variations thereof, denotes the presence of recited feature(s), element(s), method step(s), etc. and excludes any unrecited feature(s), element(s), method step(s), etc., except for ordinarily-associated impurities. The phrase “consisting essentially of” denotes the recited feature(s), element(s), method step(s), etc. and any additional feature(s), element(s), method step(s), etc. that do not materially affect the basic nature of the composition, system, or method. Many embodiments herein are described using open “comprising” language. Such embodiments encompass multiple closed “consisting of” and/or “consisting essentially of” embodiments, which may alternatively be claimed or described using such language.
- Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (32)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/838,711 US20200319196A1 (en) | 2019-04-02 | 2020-04-02 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
US17/694,295 US20220341938A1 (en) | 2019-04-02 | 2022-03-14 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828187P | 2019-04-02 | 2019-04-02 | |
US16/838,711 US20200319196A1 (en) | 2019-04-02 | 2020-04-02 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/694,295 Continuation US20220341938A1 (en) | 2019-04-02 | 2022-03-14 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200319196A1 true US20200319196A1 (en) | 2020-10-08 |
Family
ID=72661580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/838,711 Abandoned US20200319196A1 (en) | 2019-04-02 | 2020-04-02 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
US17/694,295 Pending US20220341938A1 (en) | 2019-04-02 | 2022-03-14 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/694,295 Pending US20220341938A1 (en) | 2019-04-02 | 2022-03-14 | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease |
Country Status (3)
Country | Link |
---|---|
US (2) | US20200319196A1 (en) |
EP (1) | EP3947433A4 (en) |
WO (1) | WO2020206129A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023081817A1 (en) * | 2021-11-04 | 2023-05-11 | The Regents Of The University Of Michigan | Methods to target the soluble urokinase plasminogen activator receptor pathway for the prevention and treatment of atherosclerosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112630442A (en) * | 2020-11-03 | 2021-04-09 | 浙江大学 | Plasma soluble urokinase type plasminogen activator receptor and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003077901A1 (en) * | 2002-03-08 | 2003-09-25 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
US8815519B2 (en) * | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
EP3019873A1 (en) * | 2013-07-12 | 2016-05-18 | Emory University | Diagnostic assay to predict cardiovascular risk |
WO2017040488A1 (en) * | 2015-08-31 | 2017-03-09 | Rush University Medical Center | Prediction of kidney disease, severity and related treatment approaches |
WO2017075268A1 (en) * | 2015-10-27 | 2017-05-04 | Abbott Laboratories | Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease |
-
2020
- 2020-04-02 EP EP20784156.0A patent/EP3947433A4/en active Pending
- 2020-04-02 WO PCT/US2020/026396 patent/WO2020206129A1/en unknown
- 2020-04-02 US US16/838,711 patent/US20200319196A1/en not_active Abandoned
-
2022
- 2022-03-14 US US17/694,295 patent/US20220341938A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023081817A1 (en) * | 2021-11-04 | 2023-05-11 | The Regents Of The University Of Michigan | Methods to target the soluble urokinase plasminogen activator receptor pathway for the prevention and treatment of atherosclerosis |
Also Published As
Publication number | Publication date |
---|---|
EP3947433A1 (en) | 2022-02-09 |
US20220341938A1 (en) | 2022-10-27 |
WO2020206129A1 (en) | 2020-10-08 |
EP3947433A4 (en) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kronenberg et al. | Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement | |
Hodges et al. | suPAR: a new biomarker for cardiovascular disease? | |
Ahmed et al. | Acute phase reactants as novel predictors of cardiovascular disease | |
MacIsaac et al. | Markers of and risk factors for the development and progression of diabetic kidney disease | |
Smith et al. | Renal impairment and outcomes in heart failure: systematic review and meta-analysis | |
Oikonen et al. | Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study | |
Snaedal et al. | Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival | |
US20220341938A1 (en) | Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease | |
Leiva et al. | Cardiovascular disease in myeloproliferative neoplasms: JACC: cardiooncology state-of-the-art review | |
Wang et al. | Prediction of acute kidney injury after cardiac surgery from preoperative N-terminal pro-B-type natriuretic peptide | |
Diakos et al. | Circulating and myocardial cytokines predict cardiac structural and functional improvement in patients with heart failure undergoing mechanical circulatory support | |
Yu et al. | Correlation of plasma vascular endothelial growth factor and endostatin levels with symptomatic intra-and extracranial atherosclerotic stenosis in a Chinese Han population | |
Pawlak et al. | Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients | |
Jeong et al. | Anti-cytomegalovirus antibody levels are associated with carotid atherosclerosis and inflammatory cytokine production in elderly Koreans | |
US20100323380A1 (en) | Methods for diagnosing blood vessel reocclusion | |
Baragetti et al. | -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease | |
Ezzat et al. | Prevalence of thrombophilic gene polymorphisms (FVL G1691A and MTHFR C677T) in patients with myocardial infarction | |
Xia et al. | Impact of C-reactive protein on long-term mortality in acute myocardial infarction patients with diabetes and those without | |
Elbasan et al. | Serum uric acid and slow coronary flow in cardiac syndrome X | |
Arkan et al. | The importance of circulating levels of salusin-α, salusin-β, and heregulin-β1 in atherosclerotic coronary arterial disease | |
Przybylek et al. | Novel cytokine score and cardiac allograft vasculopathy | |
Kowalik et al. | Clinical, biochemical and genetic risk factors for 30-day and 5-year mortality in 518 adult patients subjected to cardiopulmonary bypass during cardiac surgery-the INFLACOR study | |
Vos et al. | Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome | |
Yoshioka et al. | Association of CD40 ligand levels in the culprit coronary arteries with subsequent prognosis of acute myocardial infarction | |
US20060160112A1 (en) | Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAYEK, SALIM;REEL/FRAME:053860/0192 Effective date: 20200407 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |